
==== Front
Gut Pathog
Gut Pathog
Gut Pathogens
1757-4749
BioMed Central London

37106359
543
10.1186/s13099-023-00543-2
Review
Emerging role of bacterial outer membrane vesicle in gastrointestinal tract
Tian Cheng-mei 1
Yang Mei-feng 2
Xu Hao-ming 3
Zhu Min-zheng 3
Zhang Yuan 4
Yao Jun yao.jun@szhospital.com

5
Wang Li-sheng wanglsszrmyy@163.com

5
Liang Yu-jie liangyjie@126.com

6
Li De-feng ldf830712@163.com

5
1 grid.440218.b 0000 0004 1759 7210 Department of Emergency, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; the First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020 Guangdong China
2 Department of Hematology, Yantian District People’s Hospital, Shenzhen, Guangdong China
3 grid.79703.3a 0000 0004 1764 3838 Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, China
4 https://ror.org/055f13495 grid.495429.7 Department of Medical Administration, Huizhou Institute of Occupational Diseases Control and Prevention, Huizhou, Guangdong China
5 grid.440218.b 0000 0004 1759 7210 Department of Gastroenterology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; the First Affiliated Hospital, Southern University of Science and Technology), No.1017, Dongmen North Road, Luohu District, Shenzhen, 518020 People’s Republic of China
6 https://ror.org/02skpkw64 grid.452897.5 0000 0004 6091 8446 Department of Child and Adolescent Psychiatry, Shenzhen Kangning Hospital, No.1080, Cuizu Road, Luohu District, Shenzhen, 518020 People’s Republic of China
27 4 2023
27 4 2023
2023
15 209 1 2023
30 3 2023
© The Author(s) 2023
2023
https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Bacteria form a highly complex ecosystem in the gastrointestinal (GI) tract. In recent years, mounting evidence has shown that bacteria can release nanoscale phospholipid bilayer particles that encapsulate nucleic acids, proteins, lipids, and other molecules. Extracellular vesicles (EVs) are secreted by microorganisms and can transport a variety of important factors, such as virulence factors, antibiotics, HGT, and defensive factors produced by host eukaryotic cells. In addition, these EVs are vital in facilitating communication between microbiota and the host. Therefore, bacterial EVs play a crucial role in maintaining the GI tract’s health and proper functioning. In this review, we outlined the structure and composition of bacterial EVs. Additionally, we highlighted the critical role that bacterial EVs play in immune regulation and in maintaining the balance of the gut microbiota. To further elucidate progress in the field of intestinal research and to provide a reference for future EV studies, we also discussed the clinical and pharmacological potential of bacterial EVs, as well as the necessary efforts required to understand the mechanisms of interaction between bacterial EVs and gut pathogenesis.

Keywords

Bacterial
Microbiota
Outer membrane vesicle
Extracellular vesicles
Gastrointestinal tract
Science and Technology Innovation Committee of ShenzhenJCYJ20210324113802006 Guangdong Basic and Applied Basic Research Foundation2021A1515010985 Liang Yu-jie issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2023
Change history

9/23/2024

An Editorial Expression of Concern to this paper has been published: 10.1186/s13099-024-00646-4
==== Body
pmcIntroduction

The gastrointestinal (GI) tract serves as the primary site for food digestion and absorption while also acting as a gateway for toxin invasion. It performs the dual functions of digestion and absorption as well as intestinal defense, which cannot be accomplished by the digestive system alone [1]. Hidden within the GI tract is a unique "organ" called the intestinal flora, which plays a critical role in digesting chyme and protecting the intestines [2–4]. The intestinal flora consists of thousands of species and over 10 trillion bacteria, which lack a cell connection and stable extracellular matrix with host cells. As a result, communication between surface proteins and secretory proteins becomes challenging. Extracellular vesicles (EVs) produced by intestinal bacteria serve as the primary mode of material transport and communication [5], and they remain active in the intestinal microenvironment while passing through the vascular barrier to enter the bloodstream [6]. Using specific surface structures, EVs recognize and bind to either bacteria or host cells, transmitting substances and signals. Intestinal bacteria and host cells continuously secrete and accept extracellular vesicles in the intestinal microenvironment, thereby affecting the viability of bacteria and the physiological function of host cells. These vesicles transport substances and information between the two types of cells [5]. In recent years, mounting evidence has confirmed that bacteria can secrete EVs as phages, antibiotics, and eukaryotic host defense actors [7, 8]. Additionally, EVs play crucial roles in intercellular communication, virulence factor transport, horizontal gene transfer (HGT), nutrient and electron transport, and biofilm formation [9–11]. Detecting bacterial EVs enables us to understand the composition of intestinal flora and aid in diagnosis. Transforming bacterial EVs can help us develop bacterial vaccines or immune adjuvants, as well as target drug delivery. However, future work should focus on regulating intestinal flora and protecting host cells through bacterial EV preparations [12, 13].

Composition and distribution of the microflora in the gut

More than 99% of the microbiota in the intestine is composed of intestinal flora, and the number of bacteria in the intestine exceeds the number of human cells. There are at least 1000 to 150 species present in the intestinal tract, and more than 500 species can be cultured. These are concentrated in 5–7 bacterial phyla, of which Bacteroidetes and Firmicutes make up about 95% and are part of the predominant microflora (Fig. 1) [14]. Typically, these bacteria are obligate anaerobes and specialize in colonizing the intestine. Most of them are probiotics and have a symbiotic relationship with the host [15]. However, most of the sub-dominant microflora belong to foreign or transient flora with high mobility. They are mainly aerobic bacteria or facultative anaerobic bacteria and may have potential pathogenicity that can cause harm to the host [15]. The intestinal flora is complex and diverse, and its composition can be influenced by various factors, such as age, diet, exercise, heredity, drugs, living environment, regional climate, and health status [3, 4, 15–20]. The leading indicators for evaluating intestinal flora include the concentration of colonic bacteria, the diversity of intestinal bacteria, and the ratio of probiotics [21]. In healthy individuals, probiotics are usually the dominant bacterial species in the intestine. Studies have shown that the proportion of probiotics in the intestine is about 70% in healthy individuals, 25% in average individuals, and 15% in those with constipation. However, the proportion of probiotics is only about 10% in the intestine of cancer patients [21, 22]. Figure 1 provides a visual representation of the microbial density and species present in the gut.Fig. 1 The bacterial flora inhabits in regions of human gastrointestinal tract constitute a complex ecosystem. More than 10 [14] microorganisms, 500 bacteria species have been identified in GI. The upper gastrointestinal tract (stomach, duodenum, jejunum, and upper ileum) is usually contained Lactobacillus, with bacterial concentrations less than 10 [4] microorganisms/ml. By contrast, bacteria in the large intestine are dramatic increase as 10 million bacteria. Anaerobic bacteria (A. bacteria) such as Bacteroides, Enterobacter, Anaerobic Streptococcus (A. Streptococcus), Clostridium and Lactobacillus are 1000 times more abundant than facultative anaerobes such as E. coli. It is a general trend that bacteria increase in complexity and concentration as they enter the gastrointestinal tract

The intestinal microbiota is closely intertwined with the physical and chemical environment of the gut and the host cells, collectively constituting the intestinal micro-ecosystem. These elements have a reciprocal and restrictive influence on each other, always striving to maintain a dynamic equilibrium, known as intestinal microecological homeostasis [23]. An imbalance in the intestinal flora can disrupt the host cells and the physical and chemical environment of the intestine, leading to intestinal micro-ecosystem disorders. This imbalance can cause not only acute and chronic inflammatory reactions, GI dysfunction, digestive tract tumors, and other digestive system diseases but also extraintestinal diseases, such as obesity, type 2 diabetes, liver disease, atherosclerosis, infectious diseases, allergic diseases, and mental and neurological dysfunction [24].

Biogenesis of bacterial EVs

Vesicle transport is the primary means by which cells transport macromolecules. EVs are a diverse array of vesicles released by cells [25–28]. Bacteria are unicellular prokaryotes. Bacterial EVs are secreted and transported by bacteria, facilitating the transfer of information and energy conversion. This mode of transport differs from small molecule transmembrane transport and the bacterial protein I–IX secretion systems [27, 29–31].

Bacteria can be categorized into Gram-negative and Gram-positive based on Gram staining, and they differ in their secretion of EVs [27, 32, 33]. Gram-negative bacteria possess an outer membrane structure, and it is commonly believed that EVs are vesicles formed by the extrusion of the bacterial outer membrane, known as outer membrane vesicles (OMVs) [34, 35]. Most Gram-negative bacteria secrete OMVs, and it is believed that the size of bacterial OMVs is similar to that of eukaryotic microvesicles, resulting from the pinching off of the outer membrane [36]. The specific mechanism of exfoliation is not clear, but proposed models mainly include the dissociation of stable cross-links of cell walls, the enlargement of the distance between the inner and outer membranes of bacteria, the local bulging and breakage of the outer membranes, and the orderly exfoliation of OMVs under the regulation of bacterial genes [32, 33, 37–39]. Moreover, a small proportion of cells are lysed to form outer-inner membrane vesicles (OIMVs) and explosive outer membrane vesicles (EOMVs) [28, 40]. Cell lysis can be triggered by DNA damage or by the partial degradation of the peptidoglycan layer of the cell wall by autolysin to form pores, where the inner and outer membranes protrude outward to wrap the cytoplasmic components, forming vesicles that are eventually squeezed out of the bacterial surface to form OIMVs [40]. When cell death and lysis occur, membrane fragments produced by explosive lysis can re-aggregate and randomly encapsulate cytoplasmic components to form vesicles, known as EOMVs [41]. Figure 2 provides further details on the occurrence of OMVs, OIMVs, and EOMVs.Fig. 2 Biogenesis model and composition of bacterial extracellular vesicles (bEVs). The composition of bEVs includes biphospholipid layers, proteins, glycoproteins, metabolites, and nucleic acids. A bEVs derived from Gram-negative bacteria can be released through the outer membrane; (i) by reducing outer membrane-peptidoglycan protein linkages; (ii) lipid/LPS differential assembly in specific regions of the outer membrane; (iii) swelling pressure by accumulation of protein or peptidoglycan fragments in the periplasmic space; (iiii) blast by cell lysis. B bEVs derived from Gram-positive bacteria can be released from the swelling pressure caused by EV accumulation through the cell wall composed of peptidoglycan; these turgor pressure promotes membrane curvature, then bEVs are released by peptidoglycan-degrading enzymes

On the other hand, the cell wall of Gram-positive bacteria lacks an outer membrane structure and is encased with a thick peptidoglycan layer. Currently, it is widely accepted that the weakening of the peptidoglycan layer by cell wall degrading enzymes and the increase of bacterial internal pressure allow for the release of the bacterial inner membrane, and the bacterial plasma membrane wraps the cytoplasmic components and bulges outward to form vesicles known as cytoplasmic membrane vesicles (CMVs). Only a small fraction of Gram-positive bacteria secrete CMVs [27, 32, 42–47]. OMVs and CMVs differ in generation, morphology, and function, as summarized in Table 1 [48, 49]. OMVs and CMVs are collectively referred to as membrane vesicles (MVs) [29, 30]. While MVs and EVs secreted by eukaryotic cells share similarities in structure, they differ in composition and function, as outlined in Table 2 [43, 50].Table 1 Comparison between gram-negative and gram-positive extracellular vesicles

Features	Gram-negative EVs	Gram-positive EVs	References	
Origin	Outer membrane	Cytoplasmic membrane	[39]	
Size	10 nm-300 nm	20 nm-400 nm	[39]	
Components	Outer membrane proteins, periplasmic proteins, virulence factors, cytoplasmic proteins, inner membrane proteins, lipopolysaccharides, phospholipids, and peptidoglycan (10%-20%)	Cytoplasmic proteins, membrane-associated proteins, lipoteichoic acid (LTA), peptidoglycan (> 50%)	[39]	
Genetic components	sRNA, mRNA, miRNA, luminal and surface associated DNA	sRNA, extracellular and chromosomal DNA	[39, 201]	
Proteins	Outer membrane: OmpA, OmpC, OmpF, lipoprotein (Lpp), periplasmic: Alkaline phosphatase and AcrA	Single lipid membrane proteins: penicillin-binding, immunoglobulin G-binding (protein A), staphopain A, α-haemolysins, heat-shock protein	[42, 202]	
Lipids	Glycerophopholipids, phosphatidylethanolamine, phophotidylglycerol and cardiolipin	Phosphatidylglycerol, myristic and palmitic acids	[120, 202]	
Coagulation	E-selectin, P-selectin, thrombomodulin	Fibronectin binding protein, staphylocoagulase precursor, Vonwillebrand factor binding protein	[202]	
Antibiotic resistance	β-lactamase, enzyme L5, multidrug efflux protein (Mtr, Mex, TolC)	β-lactamase, Penicillin-binding proteins: PBP1, PBP2, PBP2a, PBP3 and PBP4	[202]	
Virulence factor delivery	Enzymes: phospholipase C, esterase lipase, alkaline phosphatase, serine protease Toxins: adenylatecyclase, cholera, cytolethal distending, PagJ, PagK1, VacA	InIB, LLO, IgG binding protein SbI, protective antigen, lethal factor, edema toxin, anthrolysin	[202]	
Bacterial survival	Hemin-binding protein, TonB-dependent receptors	β-lactamase protein	[202, 203]	
Bacteria adhesion and invasion	Adhesin/invasin, OmpA	Plasma binding proteins, staphopain A	[202]	
Immune evasion	Cytotoxic necrotizing factor 1, UspA1/A2	Coagulation factors, antibody degradation and sequestering factors, complement inhibition factors	[46, 202]	
Host-cell modulation	Cytolysin A, VacA toxin, CNF1, heat-liable enterotoxin, shigatoxin, Cif, flagellin, α-haemolysin	Proteolysin, β2 toxin	[202]	
Killing competing bacteria	Endopeptidase L5, murein hydrolase (Mtl, Slt), peptidoglycan hydrolase	N-aetylmuramoyl-L-alanine amindase	[202]	
Biogenesis	a. Loss or relocation of covalent linkages between the OM and the underlying peptidoglycan layer

b. Accumulation of peptidoglycan fragments in the outer leaflet of the OM

c. Misfolded proteins in periplasmic space exerting turgor pressure on OM

d. Enrichment of species-specific membrane curvature-inducing molecules

	Action of cell wall-degrading enzymes; endolysin, autolysin	[36]	
Lipids	Glycerophopholipids, phosphatidylethanolamine, phophotidylglycerol and cardiolipin	Phosphatidylglycerol, myristic and palmitic acids	[120, 202]	
Coagulation	E-selectin, P-selectin, thrombomodulin	Fibronectin binding protein, staphylocoagulase precursor, Vonwillebrand factor binding protein	[202]	

Table 2 Differences and similarities in EVs deriving from eukaryotic cells and bacteria

Eukaryotic Organism	Bacteria	
Spherical particles with a size range from 30 to 100 nm (exosomes), 100–1000 nm (MVs) or 500–2000 nm (apoptotic bodies)

Stable at 37 °C for 24 h. Sensitive to high temperature but stable in the frozen and freeze-dried states [204]

	Spherical particles with a size range from 10 to 400 nm. The maximum size is smaller than eukaryotic EVs due to smaller sized bacterial cells

Stable at 37 °C for 24 h. Greater tolerance to hot temperatures [205]. Stable in the frozen and freeze-dried states

	
Exosomes are commonly enriched in endosome-associated proteins	Mainly composed of proteins and phospholipids of the outer membrane	
Exosomes and MVs are released by healthy and damaged cells. Apoptotic bodies are released by dying cells on an apoptotic pathway	All Gram-negative bacteria produce outer membrane vesicles (OMVs) and possibly also all Gram-positive bacteria. Gram-negative bacteria can produce specific vesicles with a double layer using both the outer and inner membranes	
Originates in the plasma membrane except exosomes, which are made by the endocytic pathway	Bacteria Gram-negative and Gram-positive have a different mechanism of vesicle formation due to their distinct membrane structure, which originates in the membrane	
They are released from cells by a variety of mechanisms depending on their mode of biogenesis and they are not released homogeneously by the membrane	Production is not uniformly distributed along the bacteria surface but there are “hot spots”	
High heterogeneity in the composition of the surface and the interior	High heterogeneity in the composition of the surface and the interior	
There are universal markers such as CD40 for microvesicles or flotillin for exosomes	There are no universal markers for their identification due to their diversity	
EVs can contain different RNAs such as miRNA or mRNA but it is unusual for them to carry DNA	EVs can contain genetic material and participate in horizontal gene transfer	
Harmful cells such as tumor cells present EVs with specific and useful contents for their survival	In pathogenic bacteria, specific molecules have been found such as adhesins, toxins and/or immunomodulatory compounds as cargo of OMVs	
The main function is intercellular communication, except for apoptotic bodies, which facilitates phagocytosis	They are more relevant as a mechanism to carry away toxic compounds for bacteria than in eukaryotic cells	
Production depends on the cell type and its physiology state	Their production increases as a response to environmental stress	
A non-spontaneous biological process	A non-spontaneous biological process	

The production and secretion of bacterial EVs are influenced by the expression and regulation of bacterial genes, as well as the growth environment of bacteria [51, 52]. Bacterial genetic performance, such as bacterial adhesion, reproduction, and resistance to digestive enzymes and antibiotics, is closely related to the EVs secreted by bacteria [52, 53]. The production and secretion of EVs by bacteria are also affected by host age, dietary habits, antibiotic use, GI function, immune response, stress response, intestinal physical and chemical environment, and intestinal microbial composition [54–61]. Studies have found that the more vigorous the cell metabolism and the more stimulation the cell receives, the more EVs are secreted [30, 62, 63].

EVs can be categorized into different subtypes based on their pathogenesis and morphological structure. Each subtype represents different physiological or pathological states of cells and has different purposes and functions. Similar to eukaryotic EVs, bacterial EVs can be classified into exosomes, microvesicles, apoptotic bodies, and oncosomes. There may be additional subtypes of bacterial EVs that have yet to be discovered, and further research into the mechanisms of their occurrence can reveal different physiological states of bacteria and uncover a wider range of functions of EVs [8, 27, 40, 62].

Components of bacterial EVs

Bacterial EVs are nanoscale spherical transporters that are composed of a phospholipid bilayer membrane and have a diameter ranging from 20 to 250 nm. The membrane envelops nucleic acids, proteins, lipids, and other substances, while specific lipopolysaccharides and outer membrane proteins are embedded in the outer layer of the membrane. The asymmetry and fluidity of the membrane structure are responsible for the specific structure and function of the membrane surface [9, 64, 65], which is influenced by genetic and growth environments. EVs from different bacteria have different contents, with a focus on protein sorting, protein proportion, and DNA or RNA with different functions [66].

Proteins

Proteomic analysis has identified more than 3,500 proteins associated with OMVs [67, 68]. OMVs have been found to contain a large number of outer membrane proteins, including OmpA, OmpC, and OmpF, as well as periplasmic proteins, such as AcrA and alkaline phosphatase [67, 68]. Additionally, OMVs contain various adhesins and exotoxins [69]. The majority of OMV proteins are virulence factors that aid in the survival of bacteria by promoting bacterial growth, inhibiting competitive bacteria, evading host immunity, and resisting environmental toxins. OMVs also contain carrier proteins and channel proteins that are responsible for transport, accounting for a large proportion of OMV proteins [69]. Proteins carried by OMVs are strictly sorted based on their amino acid sequences, which contain special signal sequences known as signal peptides [70]. These signal peptides act as sorting signals that guide proteins to their target compartments. Each sorting signal is recognized by a corresponding sorting receptor. Proteins synthesized by bacterial ribosomes are transported to the inner and outer membranes, periplasm, or outside of the cell by various secretion systems. If a protein is loaded into a small vesicle, the corresponding receptor on the vesicle membrane must recognize its sorting signal signal [10, 68, 71]. The protein content of OMVs is subject to change due to alterations in gene expression and the growth environment of bacteria [70].

Nucleic acids

Bacterial EVs have been found to contain multiple types of nucleic acids [72]. EVs can carry DNA both in the lumen and on the membrane surface. The DNA in the lumen retains its antigenicity even after treatment with DNase, distinguishing it from the membrane-bound DNA. OMVs also contain miRNAs, mRNAs, and other non-coding RNAs. Several different forms of luminal DNA have been identified in OMVs secreted by Escherichia coli (E. coli), Neisseria gonorrhoeae (N. gonorrhoeae), Pseudomonas aeruginosa (P. aeruginosa), and Haemophilus influenzae (H. influenzae) [73].

OMVs have been found to contain mRNA, which can be transferred and translated after entering the host cell. Retrotransposons and other non-coding RNAs have also been reported in OMVs [74, 75]. The discovery of various nucleic acid types in OMVs highlights their importance as carriers and transmitters of genetic information, although the mechanism by which nucleic acids enter OMVs remains unclear. Similar to the intracellular transport of proteins, it is speculated that the intracellular transport of nucleic acids may involve corresponding recognition sequences through which nucleic acids are selected to enter OMVs [76, 77].

Lipids

The basic structure of EV membranes is composed of lipids, primarily phospholipids, and lipopolysaccharides. In E. coli OMVs, glycerophospholipid, phosphatidylglycerol, and phosphatidylethanolamine are important lipid components that contribute to the curvature of the OMVs [78]. Lipopolysaccharide (LPS) is an endotoxin and serves as an important antigen and ligand on the membrane surface, playing a crucial role in adhesion and activating the immune response. LPS is composed of three parts: lipid A, core polysaccharide, and O antigen. Lipid A is the most toxic component, while the O antigen is exposed on the membrane surface and serves as an important antigenic determinant [79, 80].

Role of bacterial EVs in the gut

EVs secreted by intestinal bacteria can diffuse in the intestinal microenvironment or enter the bloodstream. They are capable of recognizing specific molecules present in the environment through ligands on their membrane surface and can also be recognized and bound by specific receptors on the membrane surface of target cells. Once inside the cells, they can transmit substances and activate specific signaling pathways to transmit information [81, 82]. EVs are powerful tools that can deliver, bind, and transform substances (Fig. 2) [53, 83]. These vesicles carry various substances that have been screened by bacteria, representing the bacteria’s viability. They play a similar role to bacteria and have a significant impact on host cells, intestinal microorganisms, and the intestinal environment [12, 84].

EVs have different effects on the growth, reproduction, and colonization of bacteria of the same species. They also have both advantages and disadvantages for other bacteria and host cells. For example, they can promote the colonization of probiotics and regulate the immune response, which is beneficial to the host. However, they can also destroy the host mucosal barrier and cause inflammatory storms that are harmful to the host. The current study has identified the role of bacterial EVs in the gut, which is summarized in Table 3. This includes related studies on the role of EVs from known intestinal bacteria in the intestine [13].Table 3 Studies evaluating the role of microbiota derived BEVs as modulators of intestinal homeostasis-related processes

Bacteria	Mechanism	Experimental approach	References	
Gut ecology and food metabolism	
 Bacteriodes fragilis

 B. thetaiotaomicron

	Metabolism of complex carbohydrates to produce SFCAs: Expression of glycosyl-hydrolases, sulfatases, proteases

Cholesterol uptake: upregulation NPC1L1 receptor

Metabolites in BEVs that facilitate intestinal colonization

	Proteomics of BEVs by mass spectrometry

In vitro Caco-2 cell culture

In silico, proteomic and metabolomic analysis

	[137, 188, 206–208]	
 B. thetaiotaomicron	Assimilation of dietary Insitol-P

Macrophage internalization (Sulfatases)

	Biochemical characterization of InsP6-phosphatase

Experimental model of colitis using genetically modified mice

	[209, 210]	
 Bacteroides fragilis	Antibiotic resistance (β-lactamases)	Knockout mutant of putative β-lactamase gene	[150]	
Epithelial barrier integrity	
 E. coli Nissle 1917

 ECOR63 strain

	Upregulation of TJ proteins ZO-1 and claudin-14, downregulation of claudin-2

Protection against EPEC-induced damage: preservation of occludin and claudin-14 mRNA levels, redistribution of ZO1, amelioration of F-actin disorganization

	In vitro Caco-2 and T-84 cell cultures: RT-qPCR, confocal microscopy

In vitro Caco-2 and T-84 cell cultures infected with EPEC: RT-qPCR, confocal microscopy, paracellular permeability assays

	[116, 211]	
 E. coli Nissle 1917	Upregulation TFF3 and MMP-9 mRNA	In vivo mice model of DSS-induced colitis	[117]	
 Akkermansia muciniphila	Upregulation of ZO-1, claudin 5

Upregulation of ZO-1, ccluding, claudin-1

Upregulation of ccluding, ZO-1/2, claudin-4

	In vivo high-fat diet (HFD)-induced diabetic mice model, and Caco-2 cell culture

In vivo HFD-induced obesity mice model

In vitro Caco-2 cells challenged with LPS

	[212–214]	
Gut immunity: modulation of inflammatory responses through the intestinal epithelium	
 E. coli Nissle 1917

 ECOR12 strain

	Upregulation of IL-6, IL-8, TNF-α, IL-10, MIP1α

Upregulation of IL-22 and β-defensin

Downregulation of IL-12

Activation of NOD-1 / NF-κB pathway

	In vitro Caco-2/PBMCs cell coculture model

Ex vivo model of colonic explants

Caco-2 cells: NOD1 silencing—RIP2 kinase inhibition

	[215, 216]	
 E. coli Nissle 1917	Upregulation of IL-10; downregulation of IL-1β, TNF-α, IL-6, IL-12, IL-17, iNOS and COX-2 in colonic tissue	In vivo mice model of DSS-induced colitis	[117]	
 Lactobacillus kefir

 L. kefiranofaciens

 L. kefirgranum

	Downregulation of IL-8

Counteract oxidative stress by decreasing myeloperoxidase serum levels

	Caco-2 cells challenged with TNF-α

In vivo mice model of TNBS-induced IBD

	[217]	
Gut immunity: modulation of DCs and derived T cell responses	
 Bacteroides fragilis	Induction Treg cells (CD4 + CD25 + FOXP3 +) and IL-10 production through a mechanism that involves TLR2

Activation of autophagy. Induction of Treg cells and IL-10 production depends on functional ATG16L1 and NOD2

	In vivo mice model of TNBs-induced colitis

In vitro bone marrow-derived DCs culture

BEVs from wild-type and PSA deficient strains

Bone-marrow derived DCs from wild type, ATG16L1- and NOD2 deficient mice

In vitro cocultures of BMDCs with CD4+T cells

In vivo mice model DNBS-induced colitis

	[94, 96]	
 Bacteroides vulgatus mpk	Induction of DC tolerance via TLR2 and TLR4

Upregulation of co-stimulatory molecules including MHC-II, CD40, CD80 and CD86 in CD11c+ cells

	In vitro bone marrow-derived DCs culture

TLR4/TLR2 knockout mice model

	[218]	
 Lactobacillus rhamnosus JB-1	Increased production of IL-10 and

regulatory (CD4+CD25+FOXP3+) T cells

	In vitro bone marrow-derived DCs culture

In vivo mice model

	[219]	
 Lactobacillus sakei	Enhance IgA expression	Ex vivo model of murine Peyer's patches	[220]	
 Bifidobacterium bifidum LMG13195	Promote differentiation to regulatory T cells (CD4+CD25+FOXP3+) and IL-10 secretion	In vitro model of monocyte-derived DCs co-cultivated with CD4+ T cells	[221]	
 Bifidobacterium longum	Apoptosis of bone-marrow-derived mast cells through ESBP vesicular protein	In vivo mouse model of allergen-induced food allergy	[222]	
 E. coli Nissle 1917

 Commensal E. coli

	Upregulation of driver Th cytokines by DCs in a strain-specific manner

Differential induction of Th1, Th2, Th17/Th22 and T regulatory responses

Regulation of key miRNAs in immunity (miR-155, miR-146a/b and miR-let7i)

Differential modulation of miRNAs involved in tolerogenic responses (miR-125a/99b/let7e, miR-125b, miR-24)

	In vitro model of monocyte-derived DCs co-cultivated with CD4+ T cells

In vitro model of monocyte-derived DCs: RNA seq approaches to identify differential expressed miRNAs

	[223, 224]	

Host cells

Intestinal immune cells

EVs recognize and stimulate immune cells through pathogen-associated molecular patterns (PAMPs), mainly including specific antigens, such as LPS, peptidoglycan on the surface of the membrane, and DNA in the cell. They combine with pattern recognition receptors (PRRs) for target recognition [85, 86]. PRRs associated with bacterial EVs include Toll-like receptors (TLRs) on the cell surface, such as TLR4 activated by LPS, and NOD-like receptors (NLRs) in cells, such as NOD1 and NOD2, activated by peptidoglycan components. Cysteine-containing aspartic proteolytic enzymes (Caspases), such as Caspase-11, which act as intracellular receptors for LPS, mediate the activation of an intracellular inflammatory pathway in OMVs (Fig. 3) [87].Fig. 3 Bacterial outer membrane vesicles play an important role in bacterial interactions with human intestinal epithelial cells and intestinal immune cells

When bacterial EVs recognize and bind to immune cells, whether they are beneficial to host immune regulation depends on the source of bacteria and the substances they carry [88–90]. Firstly, LPS and peptidoglycan on the surface can stimulate intestinal immune cells, trigger an inflammatory response, and maintain normal intestinal immune function. However, they can also trigger immunosuppression, an excessive immune response, or induce immune tolerance, which may lead to bacterial invasion or infection of the host and enable the bacteria to evade the host's immune response [91, 92]. Secondly, sDNA or DNA antigenicity or specific virulence factors in EVs can invade immune cells by endocytosis or endocytosis, affect the expression of inflammatory factors in immune cells, induce apoptosis of immune cells, and create conditions for bacterial invasion or infection [87, 93].

EVs derived from probiotics have mostly been shown to have beneficial effects on host immune regulation. For example, OMVs secreted by Bacteroides fragilis (B. fragilis) carry polysaccharide A (PSA) and are delivered to intestinal dendritic cells, which can induce CD4 + regulatory T cells (Tregs) to produce IL-10, down-regulating inflammatory responses and effectively ameliorating DSS-induced colitis of the colon [94–96]. Similarly, OMVs secreted by Akkermansia muciniphila (A. muciniphila) have been shown to significantly down-regulate DSS-induced colitis in mice and play an important role in regulating inflammatory immune response and maintaining the intestinal immune barrier [97]. Lactobacillus paracasei (L. paracasei) is a probiotic with anti-inflammatory properties, and in vitro studies have shown that EVs from L. paracasei (LpEVs) can down-regulate the expression of proinflammatory cytokines, such as IL-1α, IL-1β, IL-2, and TNF-α, and up-regulate the expression of anti-inflammatory cytokines, such as IL-10 and TGF-β. Additionally, LpEVs can inhibit the activation of inflammatory proteins, such as COX-2, iNOS, NF-κB, and nitric oxide (NO), in signal transduction pathways and significantly inhibit the inflammatory response of human colon adenocarcinoma HT-29 cells induced by LPS. Animal experiments have also demonstrated that oral administration of LpEVs can significantly prevent the reduction in body weight, colon length, and disease activity index (DAI), thus attenuating clinical signs in DSS-induced mice [98].

According to Kim et al. [99], EVs derived from pathogenic bacteria often result in host immune abnormalities [99]. For example, E. coli OMVs transmit virulence factors to host intestinal macrophages, which up-regulate the expression of proinflammatory cytokines, such as IL-6 and TNF-α. This leads to systemic inflammatory response syndrome (SIRS) and sepsis. Additionally, the heat-labile enterotoxin (LT) on the surface of enterotoxigenic E. coli OMVs interacts directly with host cells through PRRs, activating proinflammatory signaling pathways and chemokines expressed by host cells and ultimately causing inflammatory responses [100–102]. Furthermore, Vibrio cholerae (V. cholerae) O395 OMVs are taken up by intestinal epithelial cells through caveolin-mediated endocytosis of outer membrane porins (OmpU and OmpT). This induces the expression of proinflammatory cytokines (such as IL-8 and GM-CSF) and chemokines (such as CCL2 and CCL20), leading to the polarization of T cells to Th2/Th17 and causing an inflammatory response [103, 104]. In the case of Helicobacter pylori (H. pylori), OMVs bind to human monocytes and deliver virulence factors, such as vacuolating cytotoxin (VacA), strongly up-regulating the expression of inflammatory cytokines, such as IL-6 and IL-10. This inhibits the proliferation of CD4 + T cells and induces T cell apoptosis [105]. Flagellated bacteria, such as Salmonella typhimurium (S. typhimurium) and Pseudomonas aeruginosa, release OMVs that cause strong NLRC4-mediated caspase-1 activation and IL-1β secretion in macrophages in an endocytosis-dependent manner, promoting an inflammatory response [106]. Besides, Acinetobacter baumannii (A. baumannii) OMVs containing the virulence factor OmpA target mitochondria in mice and disrupt the mitochondrial morphology of mouse macrophages [107, 108].

Intestinal epithelial cells

Bacterial EVs are capable of being recognized by intestinal epithelial cells and can enter them through various mechanisms, including macropinocytosis and clathrin-mediated endocytosis, in order to transmit substances or signals [10]. Depending on the components of OMVs, they may provide nutrients and digestive enzymes that are necessary for metabolism and help repair the intestinal epithelial barrier. However, they may also have harmful effects, such as damaging the intestinal epithelial cells, destroying the intestinal epithelial barrier, and inducing intestinal epithelial cell death, including apoptosis, necrosis, autophagy, and other harmful effects [99, 109–114].

Bacteroides OMVs have been discovered to carry human therapeutic keratinocyte growth factor 2 (KGF-2), which promotes the repair of intestinal epithelial cells in DSS-induced colitis in mice after oral administration [115]. Other studies have demonstrated that the oral administration of EVs secreted by E. coli Nissle 1917 (EcN), L. paracasei, and B. fragilis can promote the repair of intestinal epithelial cells and the intestinal mucosal barrier in DSS model mice, significantly improving the inflammatory response [98, 116, 117]. OMVs secreted by EcN and a human E. coli strain containing the tcpC gene (ECOR 63) can up-regulate ZO1 and claudin14 while down-regulating claudin2 in intestinal epithelial cells, which helps enhance the tight junction between intestinal epithelial cells and reduce intestinal permeability (Fig. 3) [116].

Studies have demonstrated that OMVs secreted by various enterobacteria contain OMV-related virulence factors that can trigger the death of human intestinal epithelial cells, as well as the release of inflammatory factors [118]. The outbreak strain E. coli O104: H4 has been found to release OMVs carrying virulence factors, including Shiga toxin (Stx2a), which enters into intestinal epithelial cells, targets the mitochondria, and induces the release of cytochrome C. This, in turn, activates the caspase-9 and caspase-3 pathways, leading to the formation of apoptotic bodies and the apoptosis of intestinal epithelial cells [113]. [113]. Enterohemorrhagic E. Coli (EHEC) releases OMVs containing the virulence factor EHEC hemolysin (EHEC-Hly), which is taken up into lysosomes through endocytosis by intestinal epithelial cells. EHEC-Hly then escapes from lysosomes and targets mitochondria, causing a decrease in mitochondrial transmembrane potential and the release of cytochrome C. This induces the formation of apoptotic bodies and triggers apoptosis of intestinal epithelial cells by activating caspase-9 conduction channels [119, 120].

In Crohn’s disease (CD), the endoplasmic reticulum-localized stress response protein (ER-localized stress response protein, Gp96) is overexpressed on the surface of ileal epithelial cells. PAMP molecules carried by OMVs derived from Adherent-invasive E. coli (AIEC) recognize and bind to Gp96 receptors on the surface of intestinal epithelial cells, promoting AIEC invasion and mediating the destruction of intestinal mucosal epithelial cells in CD) [110, 121]. Fusobacterium nucleatum (F. nucleatum) secretes EVs containing a variety of virulence factors that promote M1 polarization of macrophages, leading to oxidative stress injury of intestinal epithelial cells. These EVs also activate receptor-interacting protein kinase 1 (RIPK1) and receptor-interacting protein kinase 3 (RIPK3), ultimately leading to the activation of caspase-3-related signaling pathways. This promotes programmed cell necrosis of intestinal epithelial cells and destruction of the intestinal epithelial barrier [122].

GI tumor cells

Research on the effect of bacterial EVs on GI tumor cells is still in its early stages. However, current studies have found that some bacterial EVs can invade host cells, causing chronic inflammatory responses, damaging genetic material, and increasing the risk of host cell canceration [123]. Bacterial EVs have also been found to be capable of crossing physiological barriers and selectively accumulating near tumor cells, potentially altering the tumor microenvironment (TME) [124, 125].

Bacterial EVs use enhanced permeation and retention (EPR) effects and EPMP antigen molecules to induce tumor immune responses. Whether EVs can recognize introduced cells in tumor tissues and induce targeted tumor cell death requires further research. Nevertheless, modifying bacterial EVs to load chemotherapeutic drugs or anti-tumor components may be a new direction for anti-tumor therapy in the future [126, 127]. Animal experiments have shown that a mixture of Bifidobacterium lactis (B. lactis) and Lactobacillus rhamnosus (L. rhamnosus) can improve the level of intestinal butyrate, reduce the proliferation of cancerous cells, and decrease the activity of enzymes related to rectal cancer occurrence, thereby reducing the colon cancer morbidity of rats [128].

In mouse models, several intestinal microflorae have been found to promote colorectal cancer (CRC). For example, Enterotoxigenic B. fragilis (ETBF) and E. coli both carry PKS islands to promote toxin production, while F. nucleatum promotes CRC growth by stimulating inflammation and activating the β-catenin pathway [128, 129].

Exo-intestinal somatic cells

Some bacterial EVs can be absorbed into the blood and circulate to extraintestinal target cells, such as vascular endothelial cells, blood cells, and central neurons, causing diseases in cardiovascular, metabolic, and central nervous system (CNS) diseases [130]. Additionally, bacterial EVs can alter intestinal microecology and cause multi-system diseases. For instance, OMVs secreted by Bacteroides thetaiotaomicron (Bt) can be endocytosed and captured by intestinal epithelial cells through paracellular pathways and migrate to the submucosal and circulatory systems [131, 132].

Intestinal microorganisms

The composition of the intestinal microbiota is not solely determined by competition among microorganisms but also by their ability to sense and adapt to the intestinal microenvironment. The viability and defense mechanisms of microorganisms determine their ability to colonize and thrive in the gut. EVs derived from probiotic bacteria can support the growth and colonization of beneficial microorganisms while inhibiting the growth and colonization of foreign microorganisms, which are typically pathogenic or opportunistic. These EVs are crucial for maintaining the stability of the intestinal microbiota. When the microbiota becomes dysbiotic, pathogenic EVs can inhibit the growth and colonization of probiotics, alter the structure of the microbiota, and disrupt the homeostasis of the intestinal microecology.

Bacteria secrete EVs to deliver essential nutrients, functional genes, and enzymes with varying functions to the same flora. This enables the bacteria to enhance their viability and survive in the changing microenvironment of the intestine [133, 134]. Bifidobacterial EVs contain mucin-binding proteins that promote the colonization of bifidobacteria in the intestinal mucosa [135]. Similarly, Bacteroides ovatus (B. ovatus) OMVs carry inulin-degrading enzymes, which can degrade inulin and produce nutrients to support the growth of other Bacteroides species that cannot utilize inulin [136]. Proteomic analysis has revealed that OMVs of B. fragilis and Bacteroides thetaiotaomicron (B. thetaiotaomicron) selectively package a large number of carbohydrate hydrolysis and proteolytic enzymes that can digest and absorb various polysaccharides. These OMVs provide nutrients for bacteria that cannot decompose polysaccharides and help maintain the stability of the intestinal microecology [136, 137].

Furthermore, OMVs secreted by normal H. pylori have been found to promote biofilm formation in non-membranous H. pylori strains, demonstrating their ability to enhance biofilm formation [136].

EVs secreted by bacteria have the ability to transfer virulence factors to competitive flora and host cells. This can result in structural damage or dysfunction of competitive flora and host cells and even lead to cell death [138]. However, host cells and competing flora have corresponding defense mechanisms to resist the destructive effects of virulence factors, and they are constantly fighting and evolving, with the winner surviving and the loser migrating [139].

For instance, OMVs isolated from the foodborne pathogen E. coli O157:H7 have been shown to transfer virulence factors and other genetic material to recipient bacteria, such as E. coli JM109 or Salmonella enterica serovar irritable bowel [140]. This transfer enhances the cytotoxicity and defense ability of recipient bacteria [141]. Burkholderia cepacia (B. cepacia) have been shown to have strong antibacterial activity against A. baumannii, S. aureus, multidrug-resistant A. baumannii, methicillin-resistant S. aureus, and fungal pathogens. Further chemical analysis of OMVs derived from Burkholderia tylanica reveals that they carry peptidoglycan hydrolase and proteolytic enzymes, as well as antibacterial molecules, such as 4-hydroxy-2-alkylquinoline and rhamnolipid compounds. These molecules can affect ionophores, iron chelation, immunomodulation, and intercellular communication [142].

In addition, EVs secreted by bacteria can also carry defense factors, including virulence factors produced by various bacteria, toxic molecules in the environment, phage invasion, and host immune response. For instance, P. aeruginosa OMVs carry extracellular DNA, which not only mediates evasion of the host immune response but also promotes resistance to aminoglycoside antimicrobial agents [143]. Moreover, bacterial EVs are the primary means of HGT for spreading antibiotic resistance genes (ARGs), leading to reduced therapeutic efficiency of antibiotics and posing a serious threat to human health [144–146]. EVs can also transfer β-lactam resistance genes into and out of bacterial species, enhancing resistance to β-lactam antibiotics in many bacteria [147, 148]. Additionally, the number of active bacteriophages is significantly reduced by about 90% after co-incubation of T4 bacteriophage and EVs, indicating that EVs can combine irreversibly with T4 bacteriophages and thus significantly reduce their numbers in the environment. This, in turn, reduces the chance of bacterial infection by bacteriophages, as measured by the number of plaque-forming units [149].

Intestinal environment

The contents of the intestine primarily include chyme, mucus, and bacteria. Mucus is the exocrine fluid secreted by host cells, while the chyme is the digested food by the GI tract and serves as a shared resource for both host and bacteria. Each bacterium competes for high-quality resources and degrades harmful substances. Bacteria secrete EVs that carry digestive enzymes and transformed nutrients, which integrate into the intestinal chemical environment, digest chyme, provide nutrients, and transform harmful substances to bacteria, such as immune antibodies, antibiotics, toxic molecules, and phages, to improve the chemical environment for bacteria. Additionally, OMVs contain numerous enzymes that can degrade biological macromolecules. Therefore, when macromolecular substances are present in the living environment of bacteria, the release of OMVs can degrade them, enabling the bacteria to absorb and utilize these nutrients effectively [5, 27]. Secondly, OMVs have the ability to adsorb and bind antibiotics, thereby reducing their concentration, carrying antibiotic hydrolase, degrading antibiotics, and horizontally transferring ARGs to enhance the antibiotic resistance of bacteria [5, 7]. For instance, EVs released from S. Aureus under the stress of ampicillin contain a large number of proteases that can degrade β-lactam antibiotics and neutralize them in the environment [58]. Furthermore, EVs secreted by Bacteroides spp. containing β-lactamase can hydrolyze β-lactam antibiotics, reduce the concentration of antibiotics in the intestinal microenvironment, and improve the survival rate of intestinal symbiotic bacteria [150]. In a study, it has been reported that polymyxin treatment can induce sewage bacterial communities to produce a large number of EVs in the real environment, and these EVs can potentially reduce the concentration of antibiotics in water [151]. It has also been observed that polymyxin B and colistin, which are polypeptide antibiotics, can induce E. coli to release EVs that can adsorb antimicrobial peptides, thus eliminating the killing effect of these peptides on bacteria, possibly due to the binding of LPS carried by EVs to antimicrobial peptides [149, 152, 153].

Although excreted feces still contain a significant number of intestinal bacterial EVs, these EVs can remain stable and active in vitro. They carry a diverse range of enzymes and active molecules that degrade intestinal chyme, which can alter the characteristics of intestinal contents or feces, stimulate the mechanical movement of the intestine, and influence defecation patterns. In general, probiotics and their EVs can stimulate GI motility, improve stool characteristics, and promote regular bowel movements. In cases of dysbiosis, pathogenic bacterial EVs can weaken GI motility, result in dry stools, and cause constipation or diarrhea.

Potential application of bacterial EVs in GI

Bacterial EVs play a wide range of roles in the GI system. Although still in the basic research stage, bacterial EVs exhibit greater diversity and functionality than somatic EVs. They possess strong immunogenicity and can be conveniently detected in feces, urine, blood, and other bodily fluids. Obtaining bacterial EVs is relatively easy, thanks to mature bacterial culture and strain isolation technologies. Moreover, ideal EVs can be obtained through regulation. Bacterial EVs hold immense potential in disease diagnosis, vaccine or immune adjuvant development, intestinal microecology maintenance, and drug delivery. Currently, research technology presents the biggest obstacle to realizing this potential [154, 155]. However, as EV research technology matures, bacterial EVs will likely demonstrate even greater application potential (Fig. 4).Fig. 4 The advantages and challenges of bacterial-derived outer membrane vesicles. OMV possess inherent adjuvanticity

Diagnostic biomarkers

By detecting changes in bacterial EVs in bodily fluids, such as blood, feces, urine, and others, we can gain insight into the composition of the gut microbiota and identify imbalances in a timely manner. These bacterial EVs carry a large number of specific biological macromolecules that serve as the basis for the directional recognition and immunogenicity of bacterial EVs and are also key molecules in the development of intestinal and extraintestinal diseases. Discovering new biomarkers for the diagnosis of GI and extraintestinal diseases, as well as monitoring disease progression and treatment efficacy, is of great importance [156, 157]. For example, the levels of antibacterial EV antibodies in the blood of patients with bronchial asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are found to be significantly higher than those of healthy controls, indicating that measuring EVs in these patients may serve as a diagnostic biomarker [158]. It is believed that in the near future, specific components of bacterial EVs in human bodily fluids can be identified to aid in the diagnosis of intestinal diseases.

Therapeutics

Bacterial EVs have a significant impact on host cells and intestinal microorganisms, rendering them a potential therapeutic tool for regulating gut microbiota imbalances and improving immune function. By modulating the balance of the gut microbiota and maintaining intestinal immune barriers, bacterial EVs can indirectly improve the intestinal microenvironment, protect the intestinal epithelial and mucus barriers, and enhance intestinal digestion, absorption, and defecation functions.

Regulation of flora disorder

Dysbiosis is considered to be the primary factor or a concurrent change in the development of various diseases, and the regulation of gut microbiota is becoming a key aspect of disease treatment. Traditionally, antibiotics, oral probiotics, and other methods have been used to control pathogenic bacteria. However, in some patients, these methods are ineffective and may even result in antibiotic-associated diarrhea. Fecal microbiota transplantation (FMT) has been successful in treating refractory diarrhea [159]. Compared to the direct administration of microbial agents, using bacterial EVs as a therapeutic approach has several advantages, such as the ability to cross the intestinal barrier, low toxicity, high plasticity, and specificity [155]. The future direction is to use EVs to control bacteria and maintain the homeostasis of gut microbiota through EVs, which can be more accurate and effective. The introduction of EVs from probiotics can not only inhibit the reproduction and colonization of pathogenic bacteria but also provide nutrients for normal gut microbiota and resist harmful substances, such as reactive oxygen species, antibiotics, and antimicrobial peptides [53].

Regulation of immune function

Bacterial EVs are known to carry specific immunogens and PAMP molecules that are related to the parent bacteria. They have strong immunogenicity and immune cell recognition ability, which makes them suitable for developing bacterial outer membrane vesicle vaccines or immune adjuvants [85, 93, 160]. For example, some countries, such as Cuba, Norway, New Zealand, and the Netherlands, have developed monovalent vaccines against local prevalent strains of group B meningococcal (MenB) using detergent-extracted outer membrane vesicles (dOMVs) as one of the primary antigens [161–164]. The process of dOMV detergent extraction reduces LPS/lipoprotein content and hence OMV endotoxicity. It can also induce the production of bactericidal antibodies against cell-surface outer-membrane proteins (OMPs) [165]. Based on this, a polyvalent MenB vaccine (MenB-4C) was developed by Novartis (China) Biomedical Research Co. in 2013. This vaccine contains dOMV and three recombinant proteins, and it can cover 66–91% of MenB strains worldwide [165–167]. EVs are known to carry a significant amount of LPS, which not only acts as a potent immunogen but also generates a strong heat source. LPS is a key component of virulence factors, which can cause damage to host cells, trigger immune cell inflammation, and even lead to death [168, 169]. However, lysozyme can bind strongly to LPS, and the complex formed by lysozyme can help to inhibit inflammatory responses. As a result, OMVs can be detoxified by lysozyme [170, 171].

Currently, OMVs are treated with detergents, such as sodium deoxycholate, to remove a large amount of LPS. However, this process can also cause the loss of some immunogenic lipoproteins [172]. To address this issue, researchers have introduced OMVs of Neisseria meningitidis (Nm) LpxL 1 mutant gene, which converts lipid A from six fatty acyl chains to five fatty acyl chains. This modification has been shown to reduce pyrogen toxicity to the host while retaining moderate immunogenicity of LPS, thus ensuring the effectiveness and safety of vaccine products. This approach is still in the clinical research Stage [173, 174]. In other studies, OMV vaccines have been developed against Mycobacterium tuberculosis (M. tuberculosis) and Staphylococcus aureus, which produce protective cellular and humoral immune responses in mice [175, 176]. Furthermore, vaccination with S. aureus OMVs has been shown to protect against active S. aureus infection [177]. Currently, OMV vaccines against other bacteria, including H. pylori, V. cholerae, and Klebsiella pneumoniae (K. pneumoniae), and genetically engineered Bacteroides OMV vaccines are in the late stages of research and development [115, 178, 179].

Another promising approach in vaccine development involves mimicking the mechanism of OMVs and incorporating specific immunogens of pathogenic bacteria into the ideal OMV vector [180–182]. For example, non-pathogenic E. coli OMVs are engineered to express Streptococcus pneumoniae (S. pneumoniae) surface glycans. These OMVs can generate immune responses comparable to commercially available Streptococcus pneumoniae vaccines [183].

To address bacterial resistance, the development of bacterial vaccines should focus on innovative solutions. In one study, bovine serum albumin (BSA) is encapsulated with OMVs to create a BSA-OMV nano-vaccine. This approach significantly improves the survival rate of mice infected with a lethal dose of carbapenem-resistant Klebsiella pneumoniae (CRKP) [184].

Drug delivery

Bacterial EVs possess stability and targetability, allowing them to recognize specific molecules and cells with an EPR effect. As non-toxic drug carriers with good human compatibility, bacterial EVs can improve the efficacy of drugs [155, 185, 186]. To prepare bacterial EVs for drug delivery, screening of suitable bacterial EVs should be done first and then transformed and modified to recognize and load drugs or bioactive substances. Specific PAMP molecules should be present on the surface of vector EVs for directionally recognizing target cells and introducing drugs and bioactive substances. Synthetic nanomaterial carriers lack the ability to replicate the surface features of vesicles, lack intercellular interaction, and lack targeting recognition ability [187]. OMVs derived from B. fragilis have the potential to be used as drug carriers for the treatment of intestinal diseases [188]. EVs secreted by Bacillus subtilis can transport across the GI epithelium, which is useful for food, nutrition, health care products, and clinical treatment [189]. [190]. Combining OMVs with miRNA can be used to treat cancer, such as intestinal cancer, where OMVs extracted from intestinal bacteria can encapsulate anti-tumor miRNA and be delivered orally to cancer tissues in the GI tract [190]. The combination of OMVs and miRNA can effectively inhibit metastatic tumor cells. E. coli OMVs encapsulating mediating pore silica and combined with 5-fluorouracil can enhance the drug concentration at a colon part and release the drug centrally in the TME, resulting in reduced systemic adverse reactions and improved treatment of CRC [191]. Levofloxacin-loaded A. baumannii OMVs can effectively invade E. coli, P. aeruginosa, and A. baumannii, kill E. coli, and produce good therapeutic effects in a mouse intestinal E. coli infection model [192]. Exogenous siRNA carried by cellular EVs can inhibit oncogene expression by targeting mRNA. Synthetic nanocarriers have made some progress in silencing oncogene expression with exogenous siRNA, and bacterial EVs are under research for this purpose [123, 193]. OMVs can also be adapted for genetic engineering and chemical engineering methods similar to eukaryotic exosomes for targeting delivery [194–199]. Targeting intestinal tissue delivery of OMVs is particularly meaningful for treating IBD [200].

Conclusions

The intestinal flora, which has coexisted with humans for hundreds of millions of years, is closely intertwined with human health and disease. The relationship between humans and microorganisms will continue to shape human health and disease in the future. Therefore, we must expand our research and knowledge of microorganisms and comprehend their evolution and variations, as this is the path towards ensuring human survival indefinitely.

EVs derived from somatic cells have shown promising results in treating GI diseases. In particular, EVs derived from intestinal epithelial cells, macrophages, and mesenchymal stem cells are currently undergoing clinical trials. However, bacterial EVs have even more diverse types and functions, stronger immunogenicity, and greater plasticity than human-derived EVs. OMVs are natural immune adjuvants that play a critical role in vaccine production, infection prevention and control, tumor treatment, and drug delivery. Bacterial EVs offer several advantages in maintaining intestinal microecology, regulating immunity, and serving as drug carriers, making them a promising candidate for a broad range of applications (Fig. 4).

However, there are several challenges that need to be addressed: (1) The biological mechanisms and structural components of bacterial EVs are not fully understood, necessitating further research. (2) Identifying OMV components is complex, and the functions of various components need to be determined. (3) Techniques for extracting, identifying, shaping, and preserving EVs are not yet ideal and can limit the development of related clinical applications. (4) Further research is required to mitigate the adverse effects of reducing the activity and toxicity of OMV surface antigens.

To overcome these obstacles, the development of small-molecule inhibitors or novel strains with bacterial toxin activity knocked out on the surface of OMV may be an effective strategy for reducing the immunogenicity of OMVs. It is reasonable to believe that with the advancement of technology, these challenges will be overcome, and OMV-based nanotechnology will develop into a powerful toolkit for intestinal targeted delivery, GI disease diagnosis, treatment, and other related fields.

Abbreviations

IBD Inflammatory bowel disease

DMAIDs Disease-modifying anti-IBD drugs

PDENs Plant-derived exosome-like nanoparticles

UC Ulcerative colitis

CD Crohn’s disease

DDSs Drug delivery systems

EXPO Exocyst-positive organelle

MVBs Multivesicular bodies, ESCRT, endosomal sorting complex required for transport

PA Phosphatidic acid

PC Phosphatidylcholines

DGDG Digalactosyldiacylglycerol

MGDG Monogalactosyldiacylglycerol

TEM Transmission electron microscopy

SEM Scanning electron microscopy

AFM Atomic force microscopy

DLS Dynamic light scattering

PE Phosphatidylethanolamine

mTOR Mammalian target of rapamycin

MAPK Mitogen-activated protein kinase

mRNA MicroRNA

sRNA Small RNA

PEG Polyethylene glycol

GDENs Grape-derived exosome-like nanoparticles

DSS Dextran sulphate sodium

GFDENs Grapefruit-derived exosome-like nanoparticles

HO-1 Heme oxygenase-1

GDENs Ginger-derived exosome-like nanoparticles

IECs Intestinal epithelial cells

LGG Lactobacillus rhamnosus

TLDENs Tea leaves-derived exosome-like nanoparticles

BDENs Broccoli-derived exosome-like nanoparticles

AMPK Adenosine monophosphate activated protein kinase

MBDENs Mulberry bark-derived exosome-like nanoparticles

AhR Aryl hydrocarbon receptor

COPS8 Constitute photomorphogenic homolog subunit 8

CDENs Carrots-derived exosome-like nanoparticles

TET8 Tetraspanin-8

PEN1 PENETRATION 1

EC1 Extracellular domains 1

TL Targeting ligand

DSPE-PEG 1, 2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly (ethylene glycol)

E. coli Escherichia coli

N. gonorrhoeae Neisseria gonorrhoeae

P. Aeruginosa Pseudomonas aeruginosa

H. influenzae Haemophilus influenzae

B. fragiles Bacteroides fragilis

A. muciniphila Akkermansia muciniphila

L. paracasei Lactobacillus paracasei

V. cholera Vibrio cholerae

H. pylori Helicobacter pylori

S. typhimurium Salmonella typhimurium

A. baumannii Acinetobacter baumannii

S. toxin Shiga toxin

F. nucleatum Fusobacterium nucleatum

B. lactis Bifidobacterium lactis

L. rhamnoses Lactobacillus rhamnosus

B. ovatus Bacteroides ovatus

B. thetaiotaomicron Bacteroides thetaiotaomicron

S. enterica Salmonella enterica

B. cepacia Burkholderia cepacia

S. aureus Staphylococcus aureus

MenB B Meningococcal

Nm Neisseria meningitidis

M. tuberculosis Mycobacterium tuberculosis

K. pneumonia Klebsiella pneumoniae

S. pneumonia Streptococcus pneumoniae

Acknowledgements

Thanks prof. Yu-qiang Nie for editing the manuscript.

Author contributions

YL contributed towards the conceiving and illustration of this manuscript. CT, DL, MY was responsible for writing of this review. YLQT, HX, JF and MZ were responsible for assisting in collecting the literature and revising this review. YZ, YN and JW provided some suggestions. JY and LW contributed to discussion. All authors read and approved the final manuscript.

Funding

This work was supported by Science and Technology Innovation Committee of Shenzhen (JCYJ20190807145617113 and JCYJ20210324113802006), Guangdong Basic and Applied Basic Research Foundation (Grant 2021A1515010985, 2023A1515011936).

Availability of data and materials

All relevant data were included in the paper.

Declarations

Ethics approval and consent to participate

No applicable.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cheng-mei Tian, Mei-feng Yang, Hao-ming Xu and Min-zheng Zhu have contributed equally to this manuscript
==== Refs
References

1. Adak A Khan MR An insight into gut microbiota and its functionalities Cell Mol life Sci CMLS 2019 76 473 493 10.1007/s00018-018-2943-4 30317530
Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol life Sci CMLS. 2019;76:473–93. 10.1007/s00018-018-2943-4.30317530
2. Gilbert JA Current understanding of the human microbiome Nat Med 2018 24 392 400 10.1038/nm.4517 29634682
Gilbert JA, et al. Current understanding of the human microbiome. Nat Med. 2018;24:392–400. 10.1038/nm.4517.29634682
3. Shetty SA Hugenholtz F Lahti L Smidt H de Vos WM Intestinal microbiome landscaping: insight in community assemblage and implications for microbial modulation strategies FEMS Microbiol Rev 2017 41 182 199 10.1093/femsre/fuw045 28364729
Shetty SA, Hugenholtz F, Lahti L, Smidt H, de Vos WM. Intestinal microbiome landscaping: insight in community assemblage and implications for microbial modulation strategies. FEMS Microbiol Rev. 2017;41:182–99. 10.1093/femsre/fuw045.28364729
4. Nogacka AM Xenobiotics formed during food processing: their relation with the intestinal microbiota and colorectal cancer Int J Mol Sci 2019 10.3390/ijms20082051 31027304
Nogacka AM, et al. Xenobiotics formed during food processing: their relation with the intestinal microbiota and colorectal cancer. Int J Mol Sci. 2019. 10.3390/ijms20082051.31027304
5. Jahromi LP Fuhrmann G Bacterial extracellular vesicles: understanding biology promotes applications as nanopharmaceuticals Adv Drug Deliv Rev 2021 173 125 140 10.1016/j.addr.2021.03.012 33774113
Jahromi LP, Fuhrmann G. Bacterial extracellular vesicles: understanding biology promotes applications as nanopharmaceuticals. Adv Drug Deliv Rev. 2021;173:125–40. 10.1016/j.addr.2021.03.012.33774113
6. Unal CM Schaar V Riesbeck K Bacterial outer membrane vesicles in disease and preventive medicine Semin Immunopathol 2011 33 395 408 10.1007/s00281-010-0231-y 21153593
Unal CM, Schaar V, Riesbeck K. Bacterial outer membrane vesicles in disease and preventive medicine. Semin Immunopathol. 2011;33:395–408. 10.1007/s00281-010-0231-y.21153593
7. Sartorio MG Pardue EJ Feldman MF Haurat MF Bacterial outer membrane vesicles: from discovery to applications Annu Rev Microbiol 2021 75 609 630 10.1146/annurev-micro-052821-031444 34351789
Sartorio MG, Pardue EJ, Feldman MF, Haurat MF. Bacterial outer membrane vesicles: from discovery to applications. Annu Rev Microbiol. 2021;75:609–30. 10.1146/annurev-micro-052821-031444.34351789
8. Pérez-Cruz C Delgado L López-Iglesias C Mercade E Outer-inner membrane vesicles naturally secreted by gram-negative pathogenic bacteria PLoS ONE 2015 10 e0116896 10.1371/journal.pone.0116896 25581302
Pérez-Cruz C, Delgado L, López-Iglesias C, Mercade E. Outer-inner membrane vesicles naturally secreted by gram-negative pathogenic bacteria. PLoS ONE. 2015;10:e0116896. 10.1371/journal.pone.0116896.25581302
9. Uddin MJ The role of bacterial membrane vesicles in the dissemination of antibiotic resistance and as promising carriers for therapeutic agent delivery Microorganisms 2020 10.3390/microorganisms8050670 33202712
Uddin MJ, et al. The role of bacterial membrane vesicles in the dissemination of antibiotic resistance and as promising carriers for therapeutic agent delivery. Microorganisms. 2020. 10.3390/microorganisms8050670.33202712
10. Schwechheimer C Kuehn MJ Outer-membrane vesicles from gram-negative bacteria: biogenesis and functions Nat Rev Microbiol 2015 13 605 619 10.1038/nrmicro3525 26373371
Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13:605–19. 10.1038/nrmicro3525.26373371
11. Li DF Extracellular vesicles: the next generation theranostic nanomedicine for inflammatory bowel disease Int J Nanomedicine 2022 17 3893 3911 10.2147/ijn.S370784 36092245
Li DF, et al. Extracellular vesicles: the next generation theranostic nanomedicine for inflammatory bowel disease. Int J Nanomedicine. 2022;17:3893–911. 10.2147/ijn.S370784.36092245
12. Díaz-Garrido N Badia J Baldomà L Microbiota-derived extracellular vesicles in interkingdom communication in the gut J Extracell Vesicles 2021 10 e12161 10.1002/jev2.12161 34738337
Díaz-Garrido N, Badia J, Baldomà L. Microbiota-derived extracellular vesicles in interkingdom communication in the gut. J Extracell Vesicles. 2021;10:e12161. 10.1002/jev2.12161.34738337
13. Bose S Aggarwal S Singh DV Acharya N Extracellular vesicles: an emerging platform in gram-positive bacteria Microbial Cell 2020 7 312 322 10.15698/mic2020.12.737 33335921
Bose S, Aggarwal S, Singh DV, Acharya N. Extracellular vesicles: an emerging platform in gram-positive bacteria. Microbial Cell. 2020;7:312–22. 10.15698/mic2020.12.737.33335921
14. Hooper LV Gordon JI Commensal host-bacterial relationships in the gut Science 2001 292 1115 1118 10.1126/science.1058709 11352068
Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115–8. 10.1126/science.1058709.11352068
15. Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome Nature 2012 486 207 214 10.1038/nature11234 22699609
Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–14. 10.1038/nature11234.22699609
16. Yatsunenko T Human gut microbiome viewed across age and geography Nature 2012 486 222 227 10.1038/nature11053 22699611
Yatsunenko T, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222–7. 10.1038/nature11053.22699611
17. Rowland I Gut microbiota functions: metabolism of nutrients and other food components Eur J Nutr 2018 57 1 24 10.1007/s00394-017-1445-8 28393285
Rowland I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57:1–24. 10.1007/s00394-017-1445-8.28393285
18. Wan MLY Ling KH El-Nezami H Wang MF Influence of functional food components on gut health Crit Rev Food Sci Nutr 2019 59 1927 1936 10.1080/10408398.2018.1433629 29381385
Wan MLY, Ling KH, El-Nezami H, Wang MF. Influence of functional food components on gut health. Crit Rev Food Sci Nutr. 2019;59:1927–36. 10.1080/10408398.2018.1433629.29381385
19. Verbeke KA Towards microbial fermentation metabolites as markers for health benefits of prebiotics Nutr Res Rev 2015 28 42 66 10.1017/s0954422415000037 26156216
Verbeke KA, et al. Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutr Res Rev. 2015;28:42–66. 10.1017/s0954422415000037.26156216
20. Hills RD Jr Gut microbiome: profound implications for diet and disease Nutrients 2019 10.3390/nu11071613 31336992
Hills RD Jr, et al. Gut microbiome: profound implications for diet and disease. Nutrients. 2019. 10.3390/nu11071613.31336992
21. Del Chierico F Phylogenetic and metabolic tracking of gut microbiota during perinatal development PLoS ONE 2015 10 e0137347 10.1371/journal.pone.0137347 26332837
Del Chierico F, et al. Phylogenetic and metabolic tracking of gut microbiota during perinatal development. PLoS ONE. 2015;10:e0137347. 10.1371/journal.pone.0137347.26332837
22. Schanche M High-resolution analyses of overlap in the microbiota between mothers and their children Curr Microbiol 2015 71 283 290 10.1007/s00284-015-0843-5 26044992
Schanche M, et al. High-resolution analyses of overlap in the microbiota between mothers and their children. Curr Microbiol. 2015;71:283–90. 10.1007/s00284-015-0843-5.26044992
23. Filyk HA Osborne LC The multibiome: the intestinal ecosystem’s influence on immune homeostasis, health, and disease EBioMedicine 2016 13 46 54 10.1016/j.ebiom.2016.10.007 27863931
Filyk HA, Osborne LC. The multibiome: the intestinal ecosystem’s influence on immune homeostasis, health, and disease. EBioMedicine. 2016;13:46–54. 10.1016/j.ebiom.2016.10.007.27863931
24. DeGruttola AK Low D Mizoguchi A Mizoguchi E Current understanding of dysbiosis in disease in human and animal models Inflamm Bowel Dis 2016 22 1137 1150 10.1097/mib.0000000000000750 27070911
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22:1137–50. 10.1097/mib.0000000000000750.27070911
25. Schorey JS Cheng Y Singh PP Smith VL Exosomes and other extracellular vesicles in host-pathogen interactions EMBO Rep 2015 16 24 43 10.15252/embr.201439363 25488940
Schorey JS, Cheng Y, Singh PP, Smith VL. Exosomes and other extracellular vesicles in host-pathogen interactions. EMBO Rep. 2015;16:24–43. 10.15252/embr.201439363.25488940
26. Mashburn-Warren LM Whiteley M Special delivery: vesicle trafficking in prokaryotes Mol Microbiol 2006 61 839 846 10.1111/j.1365-2958.2006.05272.x 16879642
Mashburn-Warren LM, Whiteley M. Special delivery: vesicle trafficking in prokaryotes. Mol Microbiol. 2006;61:839–46. 10.1111/j.1365-2958.2006.05272.x.16879642
27. Toyofuku M Nomura N Eberl L Types and origins of bacterial membrane vesicles Nat Rev Microbiol 2019 17 13 24 10.1038/s41579-018-0112-2 30397270
Toyofuku M, Nomura N, Eberl L. Types and origins of bacterial membrane vesicles. Nat Rev Microbiol. 2019;17:13–24. 10.1038/s41579-018-0112-2.30397270
28. Roier S Zingl FG Cakar F Schild S Bacterial outer membrane vesicle biogenesis: a new mechanism and its implications Microbial Cell 2016 3 257 259 10.15698/mic2016.06.508 28357362
Roier S, Zingl FG, Cakar F, Schild S. Bacterial outer membrane vesicle biogenesis: a new mechanism and its implications. Microbial Cell. 2016;3:257–9. 10.15698/mic2016.06.508.28357362
29. Wang M Nie Y Wu XL Extracellular heme recycling and sharing across species by novel mycomembrane vesicles of a gram-positive bacterium ISME J 2021 15 605 617 10.1038/s41396-020-00800-1 33037324
Wang M, Nie Y, Wu XL. Extracellular heme recycling and sharing across species by novel mycomembrane vesicles of a gram-positive bacterium. ISME J. 2021;15:605–17. 10.1038/s41396-020-00800-1.33037324
30. Obana N Immunoactive clostridial membrane vesicle production is regulated by a sporulation factor Infect Immun 2017 10.1128/iai.00096-17 28223348
Obana N, et al. Immunoactive clostridial membrane vesicle production is regulated by a sporulation factor. Infect Immun. 2017. 10.1128/iai.00096-17.28223348
31. Guerrero-Mandujano A Hernández-Cortez C Ibarra JA Castro-Escarpulli G The outer membrane vesicles: secretion system type zero Traffic 2017 18 425 432 10.1111/tra.12488 28421662
Guerrero-Mandujano A, Hernández-Cortez C, Ibarra JA, Castro-Escarpulli G. The outer membrane vesicles: secretion system type zero. Traffic. 2017;18:425–32. 10.1111/tra.12488.28421662
32. Meldolesi J Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases Clin Exp Immunol 2019 196 318 327 10.1111/cei.13274 30756386
Meldolesi J. Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases. Clin Exp Immunol. 2019;196:318–27. 10.1111/cei.13274.30756386
33. Furuyama N Sircili MP Outer membrane vesicles (OMVs) produced by gram-negative bacteria: structure, functions, biogenesis, and vaccine application Biomed Res Int 2021 2021 1490732 10.1155/2021/1490732 33834062
Furuyama N, Sircili MP. Outer membrane vesicles (OMVs) produced by gram-negative bacteria: structure, functions, biogenesis, and vaccine application. Biomed Res Int. 2021;2021:1490732. 10.1155/2021/1490732.33834062
34. Kulp A Kuehn MJ Biological functions and biogenesis of secreted bacterial outer membrane vesicles Annu Rev Microbiol 2010 64 163 184 10.1146/annurev.micro.091208.073413 20825345
Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol. 2010;64:163–84. 10.1146/annurev.micro.091208.073413.20825345
35. Kuehn MJ Kesty NC Bacterial outer membrane vesicles and the host-pathogen interaction Genes Dev 2005 19 2645 2655 10.1101/gad.1299905 16291643
Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host-pathogen interaction. Genes Dev. 2005;19:2645–55. 10.1101/gad.1299905.16291643
36. Michel LV Gaborski T Outer membrane vesicles as molecular biomarkers for gram-negative sepsis: taking advantage of nature’s perfect packages J Biol Chem 2022 298 102483 10.1016/j.jbc.2022.102483 36108741
Michel LV, Gaborski T. Outer membrane vesicles as molecular biomarkers for gram-negative sepsis: taking advantage of nature’s perfect packages. J Biol Chem. 2022;298:102483. 10.1016/j.jbc.2022.102483.36108741
37. Beveridge TJ Structures of gram-negative cell walls and their derived membrane vesicles J Bacteriol 1999 181 4725 4733 10.1128/jb.181.16.4725-4733.1999 10438737
Beveridge TJ. Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol. 1999;181:4725–33. 10.1128/jb.181.16.4725-4733.1999.10438737
38. Avila-Calderón ED Outer membrane vesicles of gram-negative bacteria: an outlook on biogenesis Front Microbiol 2021 12 557902 10.3389/fmicb.2021.557902 33746909
Avila-Calderón ED, et al. Outer membrane vesicles of gram-negative bacteria: an outlook on biogenesis. Front Microbiol. 2021;12:557902. 10.3389/fmicb.2021.557902.33746909
39. Yu YJ Wang XH Fan GC Versatile effects of bacterium-released membrane vesicles on mammalian cells and infectious/inflammatory diseases Acta Pharmacol Sin 2018 39 514 533 10.1038/aps.2017.82 28858295
Yu YJ, Wang XH, Fan GC. Versatile effects of bacterium-released membrane vesicles on mammalian cells and infectious/inflammatory diseases. Acta Pharmacol Sin. 2018;39:514–33. 10.1038/aps.2017.82.28858295
40. Pérez-Cruz C New type of outer membrane vesicle produced by the gram-negative bacterium Shewanella vesiculosa M7T: implications for DNA content Appl Environ Microbiol 2013 79 1874 1881 10.1128/aem.03657-12 23315742
Pérez-Cruz C, et al. New type of outer membrane vesicle produced by the gram-negative bacterium Shewanella vesiculosa M7T: implications for DNA content. Appl Environ Microbiol. 2013;79:1874–81. 10.1128/aem.03657-12.23315742
41. Turnbull L Explosive cell lysis as a mechanism for the biogenesis of bacterial membrane vesicles and biofilms Nat Commun 2016 7 11220 10.1038/ncomms11220 27075392
Turnbull L, et al. Explosive cell lysis as a mechanism for the biogenesis of bacterial membrane vesicles and biofilms. Nat Commun. 2016;7:11220. 10.1038/ncomms11220.27075392
42. Brown L Wolf JM Prados-Rosales R Casadevall A Through the wall: extracellular vesicles in gram-positive bacteria, mycobacteria and fungi Nat Rev Microbiol 2015 13 620 630 10.1038/nrmicro3480 26324094
Brown L, Wolf JM, Prados-Rosales R, Casadevall A. Through the wall: extracellular vesicles in gram-positive bacteria, mycobacteria and fungi. Nat Rev Microbiol. 2015;13:620–30. 10.1038/nrmicro3480.26324094
43. Vitse J Devreese B The contribution of membrane vesicles to bacterial pathogenicity in cystic fibrosis infections and healthcare associated pneumonia Front Microbiol 2020 11 630 10.3389/fmicb.2020.00630 32328052
Vitse J, Devreese B. The contribution of membrane vesicles to bacterial pathogenicity in cystic fibrosis infections and healthcare associated pneumonia. Front Microbiol. 2020;11:630. 10.3389/fmicb.2020.00630.32328052
44. Murase K Biological effect of Streptococcus pyogenes-released extracellular vesicles on human monocytic cells, induction of cytotoxicity, and inflammatory response Front Cell Infect Microbiol 2021 11 711144 10.3389/fcimb.2021.711144 34350134
Murase K, et al. Biological effect of Streptococcus pyogenes-released extracellular vesicles on human monocytic cells, induction of cytotoxicity, and inflammatory response. Front Cell Infect Microbiol. 2021;11:711144. 10.3389/fcimb.2021.711144.34350134
45. Kopparapu PK Lipoproteins are responsible for the pro-inflammatory property of staphylococcus aureus extracellular vesicles Int J Mol Sci 2021 10.3390/ijms22137099 34281154
Kopparapu PK, et al. Lipoproteins are responsible for the pro-inflammatory property of staphylococcus aureus extracellular vesicles. Int J Mol Sci. 2021. 10.3390/ijms22137099.34281154
46. Liu Y Defourny KAY Smid EJ Abee T Gram-positive bacterial extracellular vesicles and their impact on health and disease Front Microbiol 2018 9 1502 10.3389/fmicb.2018.01502 30038605
Liu Y, Defourny KAY, Smid EJ, Abee T. Gram-positive bacterial extracellular vesicles and their impact on health and disease. Front Microbiol. 2018;9:1502. 10.3389/fmicb.2018.01502.30038605
47. Toyofuku M Prophage-triggered membrane vesicle formation through peptidoglycan damage in Bacillus subtilis Nat Commun 2017 8 481 10.1038/s41467-017-00492-w 28883390
Toyofuku M, et al. Prophage-triggered membrane vesicle formation through peptidoglycan damage in Bacillus subtilis. Nat Commun. 2017;8:481. 10.1038/s41467-017-00492-w.28883390
48. Ñahui Palomino RA Vanpouille C Costantini PE Margolis L Microbiota-host communications: bacterial extracellular vesicles as a common language PLoS Pathog 2021 17 e1009508 10.1371/journal.ppat.1009508 33984071
Ñahui Palomino RA, Vanpouille C, Costantini PE, Margolis L. Microbiota-host communications: bacterial extracellular vesicles as a common language. PLoS Pathog. 2021;17:e1009508. 10.1371/journal.ppat.1009508.33984071
49. Cai W Bacterial outer membrane vesicles, a potential vaccine candidate in interactions with host cells based Diagn Pathol 2018 13 95 10.1186/s13000-018-0768-y 30537996
Cai W, et al. Bacterial outer membrane vesicles, a potential vaccine candidate in interactions with host cells based. Diagn Pathol. 2018;13:95. 10.1186/s13000-018-0768-y.30537996
50. Gill S Catchpole R Forterre P Extracellular membrane vesicles in the three domains of life and beyond FEMS Microbiol Rev 2019 43 273 303 10.1093/femsre/fuy042 30476045
Gill S, Catchpole R, Forterre P. Extracellular membrane vesicles in the three domains of life and beyond. FEMS Microbiol Rev. 2019;43:273–303. 10.1093/femsre/fuy042.30476045
51. Bonnington KE Kuehn MJ Outer membrane vesicle production facilitates LPS remodeling and outer membrane maintenance in salmonella during environmental transitions MBio 2016 10.1128/mBio.01532-16 27795394
Bonnington KE, Kuehn MJ. Outer membrane vesicle production facilitates LPS remodeling and outer membrane maintenance in salmonella during environmental transitions. MBio. 2016. 10.1128/mBio.01532-16.27795394
52. Schwechheimer C Sullivan CJ Kuehn MJ Envelope control of outer membrane vesicle production in gram-negative bacteria Biochemistry 2013 52 3031 3040 10.1021/bi400164t 23521754
Schwechheimer C, Sullivan CJ, Kuehn MJ. Envelope control of outer membrane vesicle production in gram-negative bacteria. Biochemistry. 2013;52:3031–40. 10.1021/bi400164t.23521754
53. Caruana JC Walper SA Bacterial membrane vesicles as mediators of microbe- microbe and microbe- host community interactions Front Microbiol 2020 11 432 10.3389/fmicb.2020.00432 32265873
Caruana JC, Walper SA. Bacterial membrane vesicles as mediators of microbe- microbe and microbe- host community interactions. Front Microbiol. 2020;11:432. 10.3389/fmicb.2020.00432.32265873
54. Toyofuku M Membrane vesicle formation is associated with pyocin production under denitrifying conditions in Pseudomonas aeruginosa PAO1 Environ Microbiol 2014 16 2927 2938 10.1111/1462-2920.12260 24112564
Toyofuku M, et al. Membrane vesicle formation is associated with pyocin production under denitrifying conditions in Pseudomonas aeruginosa PAO1. Environ Microbiol. 2014;16:2927–38. 10.1111/1462-2920.12260.24112564
55. Prados-Rosales R Role for Mycobacterium tuberculosis membrane vesicles in iron acquisition J Bacteriol 2014 196 1250 1256 10.1128/jb.01090-13 24415729
Prados-Rosales R, et al. Role for Mycobacterium tuberculosis membrane vesicles in iron acquisition. J Bacteriol. 2014;196:1250–6. 10.1128/jb.01090-13.24415729
56. Keenan JI Davis KA Beaugie CR McGovern JJ Moran AP Alterations in Helicobacter pylori outer membrane and outer membrane vesicle-associated lipopolysaccharides under iron-limiting growth conditions Innate Immun 2008 14 279 290 10.1177/1753425908096857 18809652
Keenan JI, Davis KA, Beaugie CR, McGovern JJ, Moran AP. Alterations in Helicobacter pylori outer membrane and outer membrane vesicle-associated lipopolysaccharides under iron-limiting growth conditions. Innate Immun. 2008;14:279–90. 10.1177/1753425908096857.18809652
57. Baumgarten T Membrane vesicle formation as a multiple-stress response mechanism enhances Pseudomonas putida DOT-T1E cell surface hydrophobicity and biofilm formation Appl Environ Microbiol 2012 78 6217 6224 10.1128/aem.01525-12 22752175
Baumgarten T, et al. Membrane vesicle formation as a multiple-stress response mechanism enhances Pseudomonas putida DOT-T1E cell surface hydrophobicity and biofilm formation. Appl Environ Microbiol. 2012;78:6217–24. 10.1128/aem.01525-12.22752175
58. Kim SW Significant increase in the secretion of extracellular vesicles and antibiotics resistance from methicillin-resistant Staphylococcus aureus induced by ampicillin stress Sci Rep 2020 10 21066 10.1038/s41598-020-78121-8 33273518
Kim SW, et al. Significant increase in the secretion of extracellular vesicles and antibiotics resistance from methicillin-resistant Staphylococcus aureus induced by ampicillin stress. Sci Rep. 2020;10:21066. 10.1038/s41598-020-78121-8.33273518
59. Bos J Cisneros LH Mazel D Real-time tracking of bacterial membrane vesicles reveals enhanced membrane traffic upon antibiotic exposure Sci Adv 2021 10.1126/sciadv.abd1033 34559560
Bos J, Cisneros LH, Mazel D. Real-time tracking of bacterial membrane vesicles reveals enhanced membrane traffic upon antibiotic exposure. Sci Adv. 2021. 10.1126/sciadv.abd1033.34559560
60. Orench-Rivera N Kuehn MJ Environmentally controlled bacterial vesicle-mediated export Cell Microbiol 2016 18 1525 1536 10.1111/cmi.12676 27673272
Orench-Rivera N, Kuehn MJ. Environmentally controlled bacterial vesicle-mediated export. Cell Microbiol. 2016;18:1525–36. 10.1111/cmi.12676.27673272
61. Devos S Membrane vesicle secretion and prophage induction in multidrug-resistant Stenotrophomonas maltophilia in response to ciprofloxacin stress Environ Microbiol 2017 19 3930 3937 10.1111/1462-2920.13793 28488744
Devos S, et al. Membrane vesicle secretion and prophage induction in multidrug-resistant Stenotrophomonas maltophilia in response to ciprofloxacin stress. Environ Microbiol. 2017;19:3930–7. 10.1111/1462-2920.13793.28488744
62. Woith E Fuhrmann G Melzig MF Extracellular vesicles-connecting kingdoms Int J Mol Sci 2019 10.3390/ijms20225695 31739393
Woith E, Fuhrmann G, Melzig MF. Extracellular vesicles-connecting kingdoms. Int J Mol Sci. 2019. 10.3390/ijms20225695.31739393
63. Andreoni F Antibiotics stimulate formation of vesicles in staphylococcus aureus in both phage-dependent and -independent fashions and via different Routes Antimicrob Agents Chemother 2019 10.1128/aac.01439-18 30509943
Andreoni F, et al. Antibiotics stimulate formation of vesicles in staphylococcus aureus in both phage-dependent and -independent fashions and via different Routes. Antimicrob Agents Chemother. 2019. 10.1128/aac.01439-18.30509943
64. van Niel G D'Angelo G Raposo G Shedding light on the cell biology of extracellular vesicles Nat Rev Mol Cell Biol 2018 19 213 228 10.1038/nrm.2017.125 29339798
van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213–28. 10.1038/nrm.2017.125.29339798
65. Quaglia M Extracellular vesicles as mediators of cellular crosstalk between immune system and kidney graft Front Immunol 2020 11 74 10.3389/fimmu.2020.00074 32180768
Quaglia M, et al. Extracellular vesicles as mediators of cellular crosstalk between immune system and kidney graft. Front Immunol. 2020;11:74. 10.3389/fimmu.2020.00074.32180768
66. Chen Y Liu L Fu H Wei C Jin Q Comparative proteomic analysis of outer membrane vesicles from Shigella flexneri under different culture conditions Biochem Biophys Res Commun 2014 453 696 702 10.1016/j.bbrc.2014.09.142 25445584
Chen Y, Liu L, Fu H, Wei C, Jin Q. Comparative proteomic analysis of outer membrane vesicles from Shigella flexneri under different culture conditions. Biochem Biophys Res Commun. 2014;453:696–702. 10.1016/j.bbrc.2014.09.142.25445584
67. Kim YS Extracellular vesicles, especially derived from gram-negative bacteria, in indoor dust induce neutrophilic pulmonary inflammation associated with both Th1 and Th17 cell responses Clin Exp Allergy J Br Soc Allergy Clin Immunol 2013 43 443 454 10.1111/cea.12085
Kim YS, et al. Extracellular vesicles, especially derived from gram-negative bacteria, in indoor dust induce neutrophilic pulmonary inflammation associated with both Th1 and Th17 cell responses. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2013;43:443–54. 10.1111/cea.12085.
68. Cahill BK Seeley KW Gutel D Ellis TN Klebsiella pneumoniae O antigen loss alters the outer membrane protein composition and the selective packaging of proteins into secreted outer membrane vesicles Microbiol Res 2015 180 1 10 10.1016/j.micres.2015.06.012 26505306
Cahill BK, Seeley KW, Gutel D, Ellis TN. Klebsiella pneumoniae O antigen loss alters the outer membrane protein composition and the selective packaging of proteins into secreted outer membrane vesicles. Microbiol Res. 2015;180:1–10. 10.1016/j.micres.2015.06.012.26505306
69. Altindis E Fu Y Mekalanos JJ Proteomic analysis of Vibrio cholerae outer membrane vesicles Proc Natl Acad Sci USA 2014 111 E1548 1556 10.1073/pnas.1403683111 24706774
Altindis E, Fu Y, Mekalanos JJ. Proteomic analysis of Vibrio cholerae outer membrane vesicles. Proc Natl Acad Sci USA. 2014;111:E1548-1556. 10.1073/pnas.1403683111.24706774
70. Jan AT Outer membrane vesicles (OMVs) of gram-negative bacteria: a perspective update Front Microbiol 2017 8 1053 10.3389/fmicb.2017.01053 28649237
Jan AT. Outer membrane vesicles (OMVs) of gram-negative bacteria: a perspective update. Front Microbiol. 2017;8:1053. 10.3389/fmicb.2017.01053.28649237
71. Lee J Kim OY Gho YS Proteomic profiling of gram-negative bacterial outer membrane vesicles: current perspectives Proteomics Clin Appl 2016 10 897 909 10.1002/prca.201600032 27480505
Lee J, Kim OY, Gho YS. Proteomic profiling of gram-negative bacterial outer membrane vesicles: current perspectives. Proteomics Clin Appl. 2016;10:897–909. 10.1002/prca.201600032.27480505
72. Valadi H Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat Cell Biol 2007 9 654 659 10.1038/ncb1596 17486113
Valadi H, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9. 10.1038/ncb1596.17486113
73. Skog J Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Nat Cell Biol 2008 10 1470 1476 10.1038/ncb1800 19011622
Skog J, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–6. 10.1038/ncb1800.19011622
74. Wei Z Coding and noncoding landscape of extracellular RNA released by human glioma stem cells Nat Commun 2017 8 1145 10.1038/s41467-017-01196-x 29074968
Wei Z, et al. Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nat Commun. 2017;8:1145. 10.1038/s41467-017-01196-x.29074968
75. Hoen Nolte-’t EN Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions Nucleic Acids Res 2012 40 9272 9285 10.1093/nar/gks658 22821563
Hoen Nolte-’t EN, et al. Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res. 2012;40:9272–85. 10.1093/nar/gks658.22821563
76. Cicero AL Stahl PD Raposo G Extracellular vesicles shuffling intercellular messages: for good or for bad Curr Opin Biol 2015 35 69 77 10.1016/j.ceb.2015.04.013
Cicero AL, Stahl PD, Raposo G. Extracellular vesicles shuffling intercellular messages: for good or for bad. Curr Opin Biol. 2015;35:69–77. 10.1016/j.ceb.2015.04.013.
77. Gyorgy B Hung ME Breakefield XO Leonard JN Therapeutic applications of extracellular vesicles: clinical promise and open questions Annu Rev Pharmacol Toxicol 2015 55 439 464 10.1146/annurev-pharmtox-010814-124630 25292428
Gyorgy B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol. 2015;55:439–64. 10.1146/annurev-pharmtox-010814-124630.25292428
78. Horstman AL Kuehn MJ Enterotoxigenic Escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles J Biol Chem 2000 275 12489 12496 10.1074/jbc.275.17.12489 10777535
Horstman AL, Kuehn MJ. Enterotoxigenic Escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles. J Biol Chem. 2000;275:12489–96. 10.1074/jbc.275.17.12489.10777535
79. Kulkarni HM Jagannadham MV Biogenesis and multifaceted roles of outer membrane vesicles from gram-negative bacteria Microbiology 2014 160 2109 2121 10.1099/mic.0.079400-0 25069453
Kulkarni HM, Jagannadham MV. Biogenesis and multifaceted roles of outer membrane vesicles from gram-negative bacteria. Microbiology. 2014;160:2109–21. 10.1099/mic.0.079400-0.25069453
80. Raetz CR Whitfield C Lipopolysaccharide endotoxins Annu Rev Biochem 2002 71 635 700 10.1146/annurev.biochem.71.110601.135414 12045108
Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635–700. 10.1146/annurev.biochem.71.110601.135414.12045108
81. Macia L Nanan R Hosseini-Beheshti E Grau GE Host- and microbiota-derived extracellular vesicles, immune function, and disease development Int J Mol Sci 2019 10.3390/ijms21010107 31877909
Macia L, Nanan R, Hosseini-Beheshti E, Grau GE. Host- and microbiota-derived extracellular vesicles, immune function, and disease development. Int J Mol Sci. 2019. 10.3390/ijms21010107.31877909
82. Bitto NJ Bacterial membrane vesicles transport their DNA cargo into host cells Sci Rep 2017 7 7072 10.1038/s41598-017-07288-4 28765539
Bitto NJ, et al. Bacterial membrane vesicles transport their DNA cargo into host cells. Sci Rep. 2017;7:7072. 10.1038/s41598-017-07288-4.28765539
83. Yáñez-Mó M Biological properties of extracellular vesicles and their physiological functions J Extracell Vesicles 2015 4 27066 10.3402/jev.v4.27066 25979354
Yáñez-Mó M, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066. 10.3402/jev.v4.27066.25979354
84. Larabi A Barnich N Nguyen HTT Emerging role of exosomes in diagnosis and treatment of infectious and inflammatory bowel diseases Cells 2020 10.3390/cells9051111 32365813
Larabi A, Barnich N, Nguyen HTT. Emerging role of exosomes in diagnosis and treatment of infectious and inflammatory bowel diseases. Cells. 2020. 10.3390/cells9051111.32365813
85. Kuipers ME Hokke CH Smits HH Nolte-’t Hoen ENM Pathogen-derived extracellular vesicle-associated molecules that affect the host immune system: an overview Front Microbiol 2018 9 2182 10.3389/fmicb.2018.02182 30258429
Kuipers ME, Hokke CH, Smits HH, Nolte-’t Hoen ENM. Pathogen-derived extracellular vesicle-associated molecules that affect the host immune system: an overview. Front Microbiol. 2018;9:2182. 10.3389/fmicb.2018.02182.30258429
86. Cecil JD Outer membrane vesicles prime and activate macrophage inflammasomes and cytokine secretion in vitro and in vivo Front Immunol 2017 8 1017 10.3389/fimmu.2017.01017 28890719
Cecil JD, et al. Outer membrane vesicles prime and activate macrophage inflammasomes and cytokine secretion in vitro and in vivo. Front Immunol. 2017;8:1017. 10.3389/fimmu.2017.01017.28890719
87. Kaparakis-Liaskos M Ferrero RL Immune modulation by bacterial outer membrane vesicles Nat Rev Immunol 2015 15 375 387 10.1038/nri3837 25976515
Kaparakis-Liaskos M, Ferrero RL. Immune modulation by bacterial outer membrane vesicles. Nat Rev Immunol. 2015;15:375–87. 10.1038/nri3837.25976515
88. Schlatterer K The mechanism behind bacterial lipoprotein release: phenol-soluble modulins mediate toll-like receptor 2 activation via extracellular vesicle release from Staphylococcus aureus MBio 2018 10.1128/mBio.01851-18 30459192
Schlatterer K, et al. The mechanism behind bacterial lipoprotein release: phenol-soluble modulins mediate toll-like receptor 2 activation via extracellular vesicle release from Staphylococcus aureus. MBio. 2018. 10.1128/mBio.01851-18.30459192
89. Johnston EL Heras B Kufer TA Kaparakis-Liaskos M Detection of bacterial membrane vesicles by NOD-like receptors Int J Mol Sci 2021 10.3390/ijms22031005 34884778
Johnston EL, Heras B, Kufer TA, Kaparakis-Liaskos M. Detection of bacterial membrane vesicles by NOD-like receptors. Int J Mol Sci. 2021. 10.3390/ijms22031005.34884778
90. Elizagaray ML Canonical and non-canonical inflammasome activation by outer membrane vesicles derived from Bordetella pertussis Front Immunol 2020 11 1879 10.3389/fimmu.2020.01879 32973778
Elizagaray ML, et al. Canonical and non-canonical inflammasome activation by outer membrane vesicles derived from Bordetella pertussis. Front Immunol. 2020;11:1879. 10.3389/fimmu.2020.01879.32973778
91. Layre E Trafficking of mycobacterium tuberculosis envelope components and release within extracellular vesicles: host-pathogen interactions beyond the wall Front Immunol 2020 11 1230 10.3389/fimmu.2020.01230 32765485
Layre E. Trafficking of mycobacterium tuberculosis envelope components and release within extracellular vesicles: host-pathogen interactions beyond the wall. Front Immunol. 2020;11:1230. 10.3389/fimmu.2020.01230.32765485
92. Schetters STT Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8(+) T cells Acta Biomater 2019 91 248 257 10.1016/j.actbio.2019.04.033 31003032
Schetters STT, et al. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8(+) T cells. Acta Biomater. 2019;91:248–57. 10.1016/j.actbio.2019.04.033.31003032
93. Lu Q Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics J Inflamm Res 2022 15 1825 1844 10.2147/jir.S353038 35310454
Lu Q, et al. Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics. J Inflamm Res. 2022;15:1825–44. 10.2147/jir.S353038.35310454
94. Chu H Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease Science 2016 352 1116 1120 10.1126/science.aad9948 27230380
Chu H, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016;352:1116–20. 10.1126/science.aad9948.27230380
95. Mazmanian SK Capsular polysaccharides of symbiotic bacteria modulate immune responses during experimental colitis J Pediatr Gastroenterol Nutr 2008 46 Suppl 1 E11 12 10.1097/01.mpg.0000313824.70971.a7 18354314
Mazmanian SK. Capsular polysaccharides of symbiotic bacteria modulate immune responses during experimental colitis. J Pediatr Gastroenterol Nutr. 2008;46(Suppl 1):E11-12. 10.1097/01.mpg.0000313824.70971.a7.18354314
96. Shen Y Outer membrane vesicles of a human commensal mediate immune regulation and disease protection Cell Host Microbe 2012 12 509 520 10.1016/j.chom.2012.08.004 22999859
Shen Y, et al. Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe. 2012;12:509–20. 10.1016/j.chom.2012.08.004.22999859
97. Kang CS Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis PLoS ONE 2013 8 e76520 10.1371/journal.pone.0076520 24204633
Kang CS, et al. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS ONE. 2013;8:e76520. 10.1371/journal.pone.0076520.24204633
98. Choi JH Lactobacillus paracasei-derived extracellular vesicles attenuate the intestinal inflammatory response by augmenting the endoplasmic reticulum stress pathway Exp Mol Med 2020 52 423 437 10.1038/s12276-019-0359-3 32123288
Choi JH, et al. Lactobacillus paracasei-derived extracellular vesicles attenuate the intestinal inflammatory response by augmenting the endoplasmic reticulum stress pathway. Exp Mol Med. 2020;52:423–37. 10.1038/s12276-019-0359-3.32123288
99. Kim JH Lee J Park KS Hong SW Gho YS Drug repositioning to alleviate systemic inflammatory response syndrome caused by gram-negative bacterial outer membrane vesicles Adv Healthcare Mater 2018 7 e1701476 10.1002/adhm.201701476
Kim JH, Lee J, Park KS, Hong SW, Gho YS. Drug repositioning to alleviate systemic inflammatory response syndrome caused by gram-negative bacterial outer membrane vesicles. Adv Healthcare Mater. 2018;7:e1701476. 10.1002/adhm.201701476.
100. Mirhoseini A Amani J Nazarian S Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it Microb Pathog 2018 117 162 169 10.1016/j.micpath.2018.02.032 29474827
Mirhoseini A, Amani J, Nazarian S. Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it. Microb Pathog. 2018;117:162–9. 10.1016/j.micpath.2018.02.032.29474827
101. Kesty NC Mason KM Reedy M Miller SE Kuehn MJ Enterotoxigenic Escherichia coli vesicles target toxin delivery into mammalian cells EMBO J 2004 23 4538 4549 10.1038/sj.emboj.7600471 15549136
Kesty NC, Mason KM, Reedy M, Miller SE, Kuehn MJ. Enterotoxigenic Escherichia coli vesicles target toxin delivery into mammalian cells. EMBO J. 2004;23:4538–49. 10.1038/sj.emboj.7600471.15549136
102. Horstman AL Kuehn MJ Bacterial surface association of heat-labile enterotoxin through lipopolysaccharide after secretion via the general secretory pathway J Biol Chem 2002 277 32538 32545 10.1074/jbc.M203740200 12087095
Horstman AL, Kuehn MJ. Bacterial surface association of heat-labile enterotoxin through lipopolysaccharide after secretion via the general secretory pathway. J Biol Chem. 2002;277:32538–45. 10.1074/jbc.M203740200.12087095
103. Zingl FG Outer membrane vesicles of vibrio cholerae protect and deliver active cholera toxin to host cells via porin-dependent uptake MBio 2021 12 e0053421 10.1128/mBio.00534-21 34076466
Zingl FG, et al. Outer membrane vesicles of vibrio cholerae protect and deliver active cholera toxin to host cells via porin-dependent uptake. MBio. 2021;12:e0053421. 10.1128/mBio.00534-21.34076466
104. Chatterjee D Chaudhuri K Vibrio cholerae O395 outer membrane vesicles modulate intestinal epithelial cells in a NOD1 protein-dependent manner and induce dendritic cell-mediated Th2/Th17 cell responses J Biol Chem 2013 288 4299 4309 10.1074/jbc.M112.408302 23275338
Chatterjee D, Chaudhuri K. Vibrio cholerae O395 outer membrane vesicles modulate intestinal epithelial cells in a NOD1 protein-dependent manner and induce dendritic cell-mediated Th2/Th17 cell responses. J Biol Chem. 2013;288:4299–309. 10.1074/jbc.M112.408302.23275338
105. Winter J Letley D Rhead J Atherton J Robinson K Helicobacter pylori membrane vesicles stimulate innate pro- and anti-inflammatory responses and induce apoptosis in Jurkat T cells Infect Immun 2014 82 1372 1381 10.1128/iai.01443-13 24421041
Winter J, Letley D, Rhead J, Atherton J, Robinson K. Helicobacter pylori membrane vesicles stimulate innate pro- and anti-inflammatory responses and induce apoptosis in Jurkat T cells. Infect Immun. 2014;82:1372–81. 10.1128/iai.01443-13.24421041
106. Yang J Bacterial outer membrane vesicle-mediated cytosolic delivery of flagellin triggers host NLRC4 canonical inflammasome signaling Front Immunol 2020 11 581165 10.3389/fimmu.2020.581165 33312172
Yang J, et al. Bacterial outer membrane vesicle-mediated cytosolic delivery of flagellin triggers host NLRC4 canonical inflammasome signaling. Front Immunol. 2020;11:581165. 10.3389/fimmu.2020.581165.33312172
107. Lindmark B Outer membrane vesicle-mediated release of cytolethal distending toxin (CDT) from Campylobacter jejuni BMC Microbiol 2009 9 220 10.1186/1471-2180-9-220 19835618
Lindmark B, et al. Outer membrane vesicle-mediated release of cytolethal distending toxin (CDT) from Campylobacter jejuni. BMC Microbiol. 2009;9:220. 10.1186/1471-2180-9-220.19835618
108. Tiku V Outer membrane vesicles containing OmpA induce mitochondrial fragmentation to promote pathogenesis of Acinetobacter baumannii Sci Rep 2021 11 618 10.1038/s41598-020-79966-9 33436835
Tiku V, et al. Outer membrane vesicles containing OmpA induce mitochondrial fragmentation to promote pathogenesis of Acinetobacter baumannii. Sci Rep. 2021;11:618. 10.1038/s41598-020-79966-9.33436835
109. Filip R An update on the role of extracellular vesicles in the pathogenesis of necrotizing enterocolitis and inflammatory bowel diseases Cells 2021 10.3390/cells10113202 34831425
Filip R. An update on the role of extracellular vesicles in the pathogenesis of necrotizing enterocolitis and inflammatory bowel diseases. Cells. 2021. 10.3390/cells10113202.34831425
110. Deo P Mitochondrial dysfunction caused by outer membrane vesicles from gram-negative bacteria activates intrinsic apoptosis and inflammation Nat Microbiol 2020 5 1418 1427 10.1038/s41564-020-0773-2 32807891
Deo P, et al. Mitochondrial dysfunction caused by outer membrane vesicles from gram-negative bacteria activates intrinsic apoptosis and inflammation. Nat Microbiol. 2020;5:1418–27. 10.1038/s41564-020-0773-2.32807891
111. Fulsundar S Molecular characterization of outer membrane vesicles released from Acinetobacter radioresistens and their potential roles in pathogenesis Microb Pathog 2015 83–84 12 22 10.1016/j.micpath.2015.04.005 25940676
Fulsundar S, et al. Molecular characterization of outer membrane vesicles released from Acinetobacter radioresistens and their potential roles in pathogenesis. Microb Pathog. 2015;83–84:12–22. 10.1016/j.micpath.2015.04.005.25940676
112. Losier TT AMPK promotes xenophagy through priming of autophagic kinases upon detection of bacterial outer membrane vesicles Cell Rep 2019 26 2150 2165.e2155 10.1016/j.celrep.2019.01.062 30784596
Losier TT, et al. AMPK promotes xenophagy through priming of autophagic kinases upon detection of bacterial outer membrane vesicles. Cell Rep. 2019;26:2150-2165.e2155. 10.1016/j.celrep.2019.01.062.30784596
113. Kunsmann L Virulence from vesicles: novel mechanisms of host cell injury by Escherichia coli O104:H4 outbreak strain Sci Rep 2015 5 13252 10.1038/srep13252 26283502
Kunsmann L, et al. Virulence from vesicles: novel mechanisms of host cell injury by Escherichia coli O104:H4 outbreak strain. Sci Rep. 2015;5:13252. 10.1038/srep13252.26283502
114. Mondal A Cytotoxic and inflammatory responses induced by outer membrane vesicle-associated biologically active proteases from vibrio cholerae Infect Immun 2016 84 1478 1490 10.1128/iai.01365-15 26930702
Mondal A, et al. Cytotoxic and inflammatory responses induced by outer membrane vesicle-associated biologically active proteases from vibrio cholerae. Infect Immun. 2016;84:1478–90. 10.1128/iai.01365-15.26930702
115. Carvalho AL Bioengineering commensal bacteria-derived outer membrane vesicles for delivery of biologics to the gastrointestinal and respiratory tract J Extracell Vesicles 2019 8 1632100 10.1080/20013078.2019.1632100 31275534
Carvalho AL, et al. Bioengineering commensal bacteria-derived outer membrane vesicles for delivery of biologics to the gastrointestinal and respiratory tract. J Extracell Vesicles. 2019;8:1632100. 10.1080/20013078.2019.1632100.31275534
116. Alvarez CS Badia J Bosch M Giménez R Baldomà L Outer membrane vesicles and soluble factors released by probiotic Escherichia coli nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells Front Microbiol 2016 7 1981 10.3389/fmicb.2016.01981 28018313
Alvarez CS, Badia J, Bosch M, Giménez R, Baldomà L. Outer membrane vesicles and soluble factors released by probiotic Escherichia coli nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. Front Microbiol. 2016;7:1981. 10.3389/fmicb.2016.01981.28018313
117. Fábrega MJ Intestinal Anti-inflammatory effects of outer membrane vesicles from Escherichia coli nissle 1917 in DSS-experimental colitis in mice Front Microbiol 2017 8 1274 10.3389/fmicb.2017.01274 28744268
Fábrega MJ, et al. Intestinal Anti-inflammatory effects of outer membrane vesicles from Escherichia coli nissle 1917 in DSS-experimental colitis in mice. Front Microbiol. 2017;8:1274. 10.3389/fmicb.2017.01274.28744268
118. Chen S Dysregulated hemolysin liberates bacterial outer membrane vesicles for cytosolic lipopolysaccharide sensing PLoS Pathog 2018 14 e1007240 10.1371/journal.ppat.1007240 30138458
Chen S, et al. Dysregulated hemolysin liberates bacterial outer membrane vesicles for cytosolic lipopolysaccharide sensing. PLoS Pathog. 2018;14:e1007240. 10.1371/journal.ppat.1007240.30138458
119. Bielaszewska M Enterohemorrhagic Escherichia coli hemolysin employs outer membrane vesicles to target mitochondria and cause endothelial and epithelial apoptosis PLoS Pathog 2013 9 e1003797 10.1371/journal.ppat.1003797 24348251
Bielaszewska M, et al. Enterohemorrhagic Escherichia coli hemolysin employs outer membrane vesicles to target mitochondria and cause endothelial and epithelial apoptosis. PLoS Pathog. 2013;9:e1003797. 10.1371/journal.ppat.1003797.24348251
120. Bielaszewska M Host cell interactions of outer membrane vesicle-associated virulence factors of enterohemorrhagic Escherichia coli O157: intracellular delivery, trafficking and mechanisms of cell injury PLoS Pathog 2017 13 e1006159 10.1371/journal.ppat.1006159 28158302
Bielaszewska M, et al. Host cell interactions of outer membrane vesicle-associated virulence factors of enterohemorrhagic Escherichia coli O157: intracellular delivery, trafficking and mechanisms of cell injury. PLoS Pathog. 2017;13:e1006159. 10.1371/journal.ppat.1006159.28158302
121. Rolhion N Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion Gut 2010 59 1355 1362 10.1136/gut.2010.207456 20587550
Rolhion N, et al. Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion. Gut. 2010;59:1355–62. 10.1136/gut.2010.207456.20587550
122. Liu L Liang L Yang C Zhou Y Chen Y Extracellular vesicles of Fusobacterium nucleatum compromise intestinal barrier through targeting RIPK1-mediated cell death pathway Gut Microbes 2021 13 1 20 10.1080/19490976.2021.1902718 34132169
Liu L, Liang L, Yang C, Zhou Y, Chen Y. Extracellular vesicles of Fusobacterium nucleatum compromise intestinal barrier through targeting RIPK1-mediated cell death pathway. Gut Microbes. 2021;13:1–20. 10.1080/19490976.2021.1902718.34132169
123. Chen Y Extracellular vesicles in inter-kingdom communication in gastrointestinal cancer Am J Cancer Res 2021 11 1087 1103 33948347
Chen Y, et al. Extracellular vesicles in inter-kingdom communication in gastrointestinal cancer. Am J Cancer Res. 2021;11:1087–103.33948347
124. Raman M Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer Gut microbes 2013 4 181 192 10.4161/gmic.23919 23511582
Raman M, et al. Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer. Gut microbes. 2013;4:181–92. 10.4161/gmic.23919.23511582
125. Qing S Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy Adv Mater 2020 32 e2002085 10.1002/adma.202002085 33015871
Qing S, et al. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy. Adv Mater. 2020;32:e2002085. 10.1002/adma.202002085.33015871
126. Amatya SB Salmi S Kainulainen V Karihtala P Reunanen J Bacterial extracellular vesicles in gastrointestinal tract cancer: an unexplored territory Cancers 2021 10.3390/cancers13215450 34771614
Amatya SB, Salmi S, Kainulainen V, Karihtala P, Reunanen J. Bacterial extracellular vesicles in gastrointestinal tract cancer: an unexplored territory. Cancers. 2021. 10.3390/cancers13215450.34771614
127. Zhang Y Fang Z Li R Huang X Liu Q Design of outer membrane vesicles as cancer vaccines: a new toolkit for cancer therapy Cancers 2019 10.3390/cancers11091314 31881642
Zhang Y, Fang Z, Li R, Huang X, Liu Q. Design of outer membrane vesicles as cancer vaccines: a new toolkit for cancer therapy. Cancers. 2019. 10.3390/cancers11091314.31881642
128. Femia AP Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats Carcinogenesis 2002 23 1953 1960 10.1093/carcin/23.11.1953 12419846
Femia AP, et al. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis. 2002;23:1953–60. 10.1093/carcin/23.11.1953.12419846
129. Rubinstein MR Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin Cell Host Microbe 2013 14 195 206 10.1016/j.chom.2013.07.012 23954158
Rubinstein MR, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195–206. 10.1016/j.chom.2013.07.012.23954158
130. Cecil JD Sirisaengtaksin N O'Brien-Simpson NM Krachler AM Outer membrane vesicle-host cell interactions Microbiol Spectr 2019 10.1128/microbiolspec.PSIB-0001-2018 30681067
Cecil JD, Sirisaengtaksin N, O’Brien-Simpson NM, Krachler AM. Outer membrane vesicle-host cell interactions. Microbiol Spectr. 2019. 10.1128/microbiolspec.PSIB-0001-2018.30681067
131. Jones EJ The Uptake, trafficking, and biodistribution of Bacteroides thetaiotaomicron generated outer membrane vesicles Front Microbiol 2020 11 57 10.3389/fmicb.2020.00057 32117106
Jones EJ, et al. The Uptake, trafficking, and biodistribution of Bacteroides thetaiotaomicron generated outer membrane vesicles. Front Microbiol. 2020;11:57. 10.3389/fmicb.2020.00057.32117106
132. Durant L Bacteroides thetaiotaomicron-derived outer membrane vesicles promote regulatory dendritic cell responses in health but not in inflammatory bowel disease Microbiome 2020 8 88 10.1186/s40168-020-00868-z 32513301
Durant L, et al. Bacteroides thetaiotaomicron-derived outer membrane vesicles promote regulatory dendritic cell responses in health but not in inflammatory bowel disease. Microbiome. 2020;8:88. 10.1186/s40168-020-00868-z.32513301
133. Roszkowiak J Interspecies outer membrane vesicles (OMVs) modulate the sensitivity of pathogenic bacteria and pathogenic yeasts to cationic peptides and serum complement Int J Mol Sci 2019 10.3390/ijms20225577 31717311
Roszkowiak J, et al. Interspecies outer membrane vesicles (OMVs) modulate the sensitivity of pathogenic bacteria and pathogenic yeasts to cationic peptides and serum complement. Int J Mol Sci. 2019. 10.3390/ijms20225577.31717311
134. Domingues S Nielsen KM Membrane vesicles and horizontal gene transfer in prokaryotes Curr Opin Microbiol 2017 38 16 21 10.1016/j.mib.2017.03.012 28441577
Domingues S, Nielsen KM. Membrane vesicles and horizontal gene transfer in prokaryotes. Curr Opin Microbiol. 2017;38:16–21. 10.1016/j.mib.2017.03.012.28441577
135. Nishiyama K Extracellular vesicles produced by Bifidobacterium longum export mucin-binding proteins Appl Environ Microbiol 2020 10.1128/aem.01464-20 32737132
Nishiyama K, et al. Extracellular vesicles produced by Bifidobacterium longum export mucin-binding proteins. Appl Environ Microbiol. 2020. 10.1128/aem.01464-20.32737132
136. Rakoff-Nahoum S Coyne MJ Comstock LE An ecological network of polysaccharide utilization among human intestinal symbionts Curr Biol CB 2014 24 40 49 10.1016/j.cub.2013.10.077 24332541
Rakoff-Nahoum S, Coyne MJ, Comstock LE. An ecological network of polysaccharide utilization among human intestinal symbionts. Curr Biol CB. 2014;24:40–9. 10.1016/j.cub.2013.10.077.24332541
137. Elhenawy W Debelyy MO Feldman MF Preferential packing of acidic glycosidases and proteases into Bacteroides outer membrane vesicles MBio 2014 5 e00909 00914 10.1128/mBio.00909-14 24618254
Elhenawy W, Debelyy MO, Feldman MF. Preferential packing of acidic glycosidases and proteases into Bacteroides outer membrane vesicles. MBio. 2014;5:e00909-00914. 10.1128/mBio.00909-14.24618254
138. Rueter C Bielaszewska M Secretion and delivery of intestinal pathogenic Escherichia coli virulence factors via outer membrane vesicles Front Cell Infect Microbiol 2020 10 91 10.3389/fcimb.2020.00091 32211344
Rueter C, Bielaszewska M. Secretion and delivery of intestinal pathogenic Escherichia coli virulence factors via outer membrane vesicles. Front Cell Infect Microbiol. 2020;10:91. 10.3389/fcimb.2020.00091.32211344
139. Koeppen K A Novel mechanism of host-pathogen interaction through sRNA in bacterial outer membrane vesicles PLoS Pathog 2016 12 e1005672 10.1371/journal.ppat.1005672 27295279
Koeppen K, et al. A Novel mechanism of host-pathogen interaction through sRNA in bacterial outer membrane vesicles. PLoS Pathog. 2016;12:e1005672. 10.1371/journal.ppat.1005672.27295279
140. Yaron S Kolling GL Simon L Matthews KR Vesicle-mediated transfer of virulence genes from Escherichia coli O157:H7 to other enteric bacteria Appl Environ Microbiol 2000 66 4414 4420 10.1128/aem.66.10.4414-4420.2000 11010892
Yaron S, Kolling GL, Simon L, Matthews KR. Vesicle-mediated transfer of virulence genes from Escherichia coli O157:H7 to other enteric bacteria. Appl Environ Microbiol. 2000;66:4414–20. 10.1128/aem.66.10.4414-4420.2000.11010892
141. Kadurugamuwa JL Beveridge TJ Membrane vesicles derived from Pseudomonas aeruginosa and Shigella flexneri can be integrated into the surfaces of other gram-negative bacteria Microbiology 1999 145 Pt 8 2051 2060 10.1099/13500872-145-8-2051 10463171
Kadurugamuwa JL, Beveridge TJ. Membrane vesicles derived from Pseudomonas aeruginosa and Shigella flexneri can be integrated into the surfaces of other gram-negative bacteria. Microbiology. 1999;145(Pt 8):2051–60. 10.1099/13500872-145-8-2051.10463171
142. Wang Y Burkholderia thailandensis outer membrane vesicles exert antimicrobial activity against drug-resistant and competitor microbial species J Microbiol 2020 58 550 562 10.1007/s12275-020-0028-1 32281050
Wang Y, et al. Burkholderia thailandensis outer membrane vesicles exert antimicrobial activity against drug-resistant and competitor microbial species. J Microbiol. 2020;58:550–62. 10.1007/s12275-020-0028-1.32281050
143. Sarkar S Release mechanisms and molecular interactions of Pseudomonas aeruginosa extracellular DNA Appl Microbiol Biotechnol 2020 104 6549 6564 10.1007/s00253-020-10687-9 32500267
Sarkar S. Release mechanisms and molecular interactions of Pseudomonas aeruginosa extracellular DNA. Appl Microbiol Biotechnol. 2020;104:6549–64. 10.1007/s00253-020-10687-9.32500267
144. Pruden A Pei R Storteboom H Carlson KH Antibiotic resistance genes as emerging contaminants: studies in northern Colorado Environ Sci Technol 2006 40 7445 7450 10.1021/es060413l 17181002
Pruden A, Pei R, Storteboom H, Carlson KH. Antibiotic resistance genes as emerging contaminants: studies in northern Colorado. Environ Sci Technol. 2006;40:7445–50. 10.1021/es060413l.17181002
145. Allen HK Call of the wild: antibiotic resistance genes in natural environments Nat Rev Microbiol 2010 8 251 259 10.1038/nrmicro2312 20190823
Allen HK, et al. Call of the wild: antibiotic resistance genes in natural environments. Nat Rev Microbiol. 2010;8:251–9. 10.1038/nrmicro2312.20190823
146. Nazarian P Tran F Boedicker JQ Modeling multispecies gene flow dynamics reveals the unique roles of different horizontal gene transfer mechanisms Front Microbiol 2018 9 2978 10.3389/fmicb.2018.02978 30564220
Nazarian P, Tran F, Boedicker JQ. Modeling multispecies gene flow dynamics reveals the unique roles of different horizontal gene transfer mechanisms. Front Microbiol. 2018;9:2978. 10.3389/fmicb.2018.02978.30564220
147. Rumbo C Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii Antimicrob Agents Chemother 2011 55 3084 3090 10.1128/aac.00929-10 21518847
Rumbo C, et al. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:3084–90. 10.1128/aac.00929-10.21518847
148. Chatterjee S Mondal A Mitra S Basu S Acinetobacter baumannii transfers the blaNDM-1 gene via outer membrane vesicles J Antimicrob Chemother 2017 72 2201 2207 10.1093/jac/dkx131 28505330
Chatterjee S, Mondal A, Mitra S, Basu S. Acinetobacter baumannii transfers the blaNDM-1 gene via outer membrane vesicles. J Antimicrob Chemother. 2017;72:2201–7. 10.1093/jac/dkx131.28505330
149. Manning AJ Kuehn MJ Contribution of bacterial outer membrane vesicles to innate bacterial defense BMC Microbiol 2011 11 258 10.1186/1471-2180-11-258 22133164
Manning AJ, Kuehn MJ. Contribution of bacterial outer membrane vesicles to innate bacterial defense. BMC Microbiol. 2011;11:258. 10.1186/1471-2180-11-258.22133164
150. Stentz R Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against β-lactam antibiotics J Antimicrob Chemother 2015 70 701 709 10.1093/jac/dku466 25433011
Stentz R, et al. Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against β-lactam antibiotics. J Antimicrob Chemother. 2015;70:701–9. 10.1093/jac/dku466.25433011
151. Maestre-Carballa L Insights into the antibiotic resistance dissemination in a wastewater effluent microbiome: bacteria, viruses and vesicles matter Environ Microbiol 2019 21 4582 4596 10.1111/1462-2920.14758 31342640
Maestre-Carballa L, et al. Insights into the antibiotic resistance dissemination in a wastewater effluent microbiome: bacteria, viruses and vesicles matter. Environ Microbiol. 2019;21:4582–96. 10.1111/1462-2920.14758.31342640
152. Steimle A Autenrieth IB Frick JS Structure and function: Lipid A modifications in commensals and pathogens Int J Med Microbiol IJMM 2016 306 290 301 10.1016/j.ijmm.2016.03.001 27009633
Steimle A, Autenrieth IB, Frick JS. Structure and function: Lipid A modifications in commensals and pathogens. Int J Med Microbiol IJMM. 2016;306:290–301. 10.1016/j.ijmm.2016.03.001.27009633
153. Brogden KA Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005 3 238 250 10.1038/nrmicro1098 15703760
Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3:238–50. 10.1038/nrmicro1098.15703760
154. Chen SZ Chen Y The role of intestinal bacteria derived extracellular vesicles in inflammatory bowel disease Zhonghua Nei Ke Za Zhi 2021 60 932 936 10.3760/cma.j.cn112138-20201013-00862 34551488
Chen SZ, Chen Y. The role of intestinal bacteria derived extracellular vesicles in inflammatory bowel disease. Zhonghua Nei Ke Za Zhi. 2021;60:932–6. 10.3760/cma.j.cn112138-20201013-00862.34551488
155. Li M Bacterial outer membrane vesicles as a platform for biomedical applications: an update J Control Release Off J Control Release Soc 2020 323 253 268 10.1016/j.jconrel.2020.04.031
Li M, et al. Bacterial outer membrane vesicles as a platform for biomedical applications: an update. J Control Release Off J Control Release Soc. 2020;323:253–68. 10.1016/j.jconrel.2020.04.031.
156. Zhou Y Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction mSystems 2018 10.1128/mSystems.00188-17 30637338
Zhou Y, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018. 10.1128/mSystems.00188-17.30637338
157. Nah G Type-2 diabetics reduces spatial variation of microbiome based on extracellur vesicles from gut microbes across human body Sci Rep 2019 9 20136 10.1038/s41598-019-56662-x 31882892
Nah G, et al. Type-2 diabetics reduces spatial variation of microbiome based on extracellur vesicles from gut microbes across human body. Sci Rep. 2019;9:20136. 10.1038/s41598-019-56662-x.31882892
158. Yang J Lung disease diagnostic model through IgG sensitization to microbial extracellular vesicles Allergy Asthma Immunol Res 2020 12 669 683 10.4168/aair.2020.12.4.669 32400132
Yang J, et al. Lung disease diagnostic model through IgG sensitization to microbial extracellular vesicles. Allergy Asthma Immunol Res. 2020;12:669–83. 10.4168/aair.2020.12.4.669.32400132
159. Weingarden AR Vaughn BP Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease Gut Microbes 2017 8 238 252 10.1080/19490976.2017.1290757 28609251
Weingarden AR, Vaughn BP. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes. 2017;8:238–52. 10.1080/19490976.2017.1290757.28609251
160. Schwab A Extracellular vesicles from infected cells: potential for direct pathogenesis Front Microbiol 2015 6 1132 10.3389/fmicb.2015.01132 26539170
Schwab A, et al. Extracellular vesicles from infected cells: potential for direct pathogenesis. Front Microbiol. 2015;6:1132. 10.3389/fmicb.2015.01132.26539170
161. Fredriksen JH Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease NIPH Ann 1991 14 67 79 1812438
Fredriksen JH, et al. Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991;14:67–79.1812438
162. Sierra GV Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba NIPH Ann 1991 14 195 207 1812432
Sierra GV, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14:195–207.1812432
163. Thornton V Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control Vaccine 2006 24 1395 1400 10.1016/j.vaccine.2005.09.043 16242221
Thornton V, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine. 2006;24:1395–400. 10.1016/j.vaccine.2005.09.043.16242221
164. Claassen I Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine Vaccine 1996 14 1001 1008 10.1016/0264-410x(96)00020-5 8873395
Claassen I, et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine. 1996;14:1001–8. 10.1016/0264-410x(96)00020-5.8873395
165. Micoli F MacLennan CA Outer membrane vesicle vaccines Semin Immunol 2020 50 101433 10.1016/j.smim.2020.101433 33309166
Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin Immunol. 2020;50:101433. 10.1016/j.smim.2020.101433.33309166
166. Masforrol Y A deeper mining on the protein composition of VA-MENGOC-BC®: an OMV-based vaccine against N. meningitidis serogroup B and C Hum Vaccin Immunother 2017 13 2548 2560 10.1080/21645515.2017.1356961 29083947
Masforrol Y, et al. A deeper mining on the protein composition of VA-MENGOC-BC®: an OMV-based vaccine against N. meningitidis serogroup B and C. Hum Vaccin Immunother. 2017;13:2548–60. 10.1080/21645515.2017.1356961.29083947
167. Beernink PT Vianzon V Lewis LA Moe GR Granoff DM A meningococcal outer membrane vesicle vaccine with overexpressed mutant FHbp elicits higher protective antibody responses in infant rhesus macaques than a licensed serogroup B vaccine MBio 2019 10.1128/mBio.01231-19 31213564
Beernink PT, Vianzon V, Lewis LA, Moe GR, Granoff DM. A meningococcal outer membrane vesicle vaccine with overexpressed mutant FHbp elicits higher protective antibody responses in infant rhesus macaques than a licensed serogroup B vaccine. MBio. 2019. 10.1128/mBio.01231-19.31213564
168. Vanaja SK Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation Cell 2016 165 1106 1119 10.1016/j.cell.2016.04.015 27156449
Vanaja SK, et al. Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation. Cell. 2016;165:1106–19. 10.1016/j.cell.2016.04.015.27156449
169. Simpson BW Trent MS Pushing the envelope: LPS modifications and their consequences Nat Rev Microbiol 2019 17 403 416 10.1038/s41579-019-0201-x 31142822
Simpson BW, Trent MS. Pushing the envelope: LPS modifications and their consequences. Nat Rev Microbiol. 2019;17:403–16. 10.1038/s41579-019-0201-x.31142822
170. Takada K Ohno N Yadomae T Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo Infect Immun 1994 62 1171 1175 10.1128/iai.62.4.1171-1175.1994 8132323
Takada K, Ohno N, Yadomae T. Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo. Infect Immun. 1994;62:1171–5. 10.1128/iai.62.4.1171-1175.1994.8132323
171. Peng LH Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma Sci Adv 2020 6 eaba2735 10.1126/sciadv.aba2735 32923586
Peng LH, et al. Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed therapy against melanoma. Sci Adv. 2020;6:eaba2735. 10.1126/sciadv.aba2735.32923586
172. Christodoulides M Heckels J Novel approaches to Neisseria meningitidis vaccine design Pathog Dis 2017 10.1093/femspd/ftx033 28369428
Christodoulides M, Heckels J. Novel approaches to Neisseria meningitidis vaccine design. Pathog Dis. 2017. 10.1093/femspd/ftx033.28369428
173. Keiser PB A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression Vaccine 2011 29 1413 1420 10.1016/j.vaccine.2010.12.039 21199704
Keiser PB, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine. 2011;29:1413–20. 10.1016/j.vaccine.2010.12.039.21199704
174. van der Ley P Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity Infect Immun 2001 69 5981 5990 10.1128/iai.69.10.5981-5990.2001 11553534
van der Ley P, et al. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun. 2001;69:5981–90. 10.1128/iai.69.10.5981-5990.2001.11553534
175. Wang X Thompson CD Weidenmaier C Lee JC Release of Staphylococcus aureus extracellular vesicles and their application as a vaccine platform Nat Commun 2018 9 1379 10.1038/s41467-018-03847-z 29643357
Wang X, Thompson CD, Weidenmaier C, Lee JC. Release of Staphylococcus aureus extracellular vesicles and their application as a vaccine platform. Nat Commun. 2018;9:1379. 10.1038/s41467-018-03847-z.29643357
176. Prados-Rosales R Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosis MBio 2014 5 e01921 e11914 10.1128/mBio.01921-14 25271291
Prados-Rosales R, et al. Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosis. MBio. 2014;5:e01921-e11914. 10.1128/mBio.01921-14.25271291
177. Choi SJ Active immunization with extracellular vesicles derived from staphylococcus aureus effectively protects against staphylococcal lung infections, mainly via th1 cell-mediated immunity PLoS ONE 2015 10 e0136021 10.1371/journal.pone.0136021 26333035
Choi SJ, et al. Active immunization with extracellular vesicles derived from staphylococcus aureus effectively protects against staphylococcal lung infections, mainly via th1 cell-mediated immunity. PLoS ONE. 2015;10:e0136021. 10.1371/journal.pone.0136021.26333035
178. Lee WH Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity Exp Mol Med 2015 47 e183 10.1038/emm.2015.59 26358222
Lee WH, et al. Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. Exp Mol Med. 2015;47:e183. 10.1038/emm.2015.59.26358222
179. Song Z Outer membrane vesicles of Helicobacter pylori 7.13 as adjuvants promote protective efficacy against Helicobacter pylori infection Front Microbiol 2020 11 1340 10.3389/fmicb.2020.01340 32733396
Song Z, et al. Outer membrane vesicles of Helicobacter pylori 7.13 as adjuvants promote protective efficacy against Helicobacter pylori infection. Front Microbiol. 2020;11:1340. 10.3389/fmicb.2020.01340.32733396
180. Gasperini G Outer membrane vesicles (OMV)-based and proteomics-driven antigen selection identifies novel factors contributing to Bordetella pertussis adhesion to epithelial cells Mol Cell Proteomics MCP 2018 17 205 215 10.1074/mcp.RA117.000045 29203497
Gasperini G, et al. Outer membrane vesicles (OMV)-based and proteomics-driven antigen selection identifies novel factors contributing to Bordetella pertussis adhesion to epithelial cells. Mol Cell Proteomics MCP. 2018;17:205–15. 10.1074/mcp.RA117.000045.29203497
181. Kunjantarachot A Phanaksri T Effective platform for the production of recombinant outer membrane vesicles in gram-negative bacteria J Microbiol Biotechnol 2022 32 621 629 10.4014/jmb.2003.03023 32522965
Kunjantarachot A, Phanaksri T. Effective platform for the production of recombinant outer membrane vesicles in gram-negative bacteria. J Microbiol Biotechnol. 2022;32:621–9. 10.4014/jmb.2003.03023.32522965
182. Ojima Y Sawabe T Konami K Azuma M Construction of hypervesiculation Escherichia coli strains and application for secretory protein production Biotechnol Bioeng 2020 117 701 709 10.1002/bit.27239 31788781
Ojima Y, Sawabe T, Konami K, Azuma M. Construction of hypervesiculation Escherichia coli strains and application for secretory protein production. Biotechnol Bioeng. 2020;117:701–9. 10.1002/bit.27239.31788781
183. Price NL Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines Sci Rep 2016 6 24931 10.1038/srep24931 27103188
Price NL, et al. Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines. Sci Rep. 2016;6:24931. 10.1038/srep24931.27103188
184. Wu G Nanoparticle reinforced bacterial outer-membrane vesicles effectively prevent fatal infection of carbapenem-resistant Klebsiella pneumoniae Nanomed Nanotechnol Biol Med 2020 24 102148 10.1016/j.nano.2019.102148
Wu G, et al. Nanoparticle reinforced bacterial outer-membrane vesicles effectively prevent fatal infection of carbapenem-resistant Klebsiella pneumoniae. Nanomed Nanotechnol Biol Med. 2020;24:102148. 10.1016/j.nano.2019.102148.
185. Alves NJ Turner KB Medintz IL Walper SA Protecting enzymatic function through directed packaging into bacterial outer membrane vesicles Sci Rep 2016 6 24866 10.1038/srep24866 27117743
Alves NJ, Turner KB, Medintz IL, Walper SA. Protecting enzymatic function through directed packaging into bacterial outer membrane vesicles. Sci Rep. 2016;6:24866. 10.1038/srep24866.27117743
186. Arigita C Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines Vaccine 2004 22 629 642 10.1016/j.vaccine.2003.08.027 14741154
Arigita C, et al. Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines. Vaccine. 2004;22:629–42. 10.1016/j.vaccine.2003.08.027.14741154
187. Wang S Gao J Wang Z Outer membrane vesicles for vaccination and targeted drug delivery Wiley Interdiscip Rev Nanomed Nanobiotechnol 2019 11 e1523 10.1002/wnan.1523 29701017
Wang S, Gao J, Wang Z. Outer membrane vesicles for vaccination and targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11:e1523. 10.1002/wnan.1523.29701017
188. Badi SA Extraction and evaluation of outer membrane vesicles from two important gut microbiota members, bacteroides fragilis and bacteroides thetaiotaomicron Cell J 2020 22 344 349 10.22074/cellj.2020.6499 31863660
Badi SA, et al. Extraction and evaluation of outer membrane vesicles from two important gut microbiota members, bacteroides fragilis and bacteroides thetaiotaomicron. Cell J. 2020;22:344–9. 10.22074/cellj.2020.6499.31863660
189. Rubio APD Transcytosis of Bacillus subtilis extracellular vesicles through an in vitro intestinal epithelial cell model Sci Rep 2020 10 3120 10.1038/s41598-020-60077-4 32080346
Rubio APD, et al. Transcytosis of Bacillus subtilis extracellular vesicles through an in vitro intestinal epithelial cell model. Sci Rep. 2020;10:3120. 10.1038/s41598-020-60077-4.32080346
190. Tran AX Periplasmic cleavage and modification of the 1-phosphate group of Helicobacter pylori lipid A J Biol Chem 2004 279 55780 55791 10.1074/jbc.M406480200 15489235
Tran AX, et al. Periplasmic cleavage and modification of the 1-phosphate group of Helicobacter pylori lipid A. J Biol Chem. 2004;279:55780–91. 10.1074/jbc.M406480200.15489235
191. Shi J Biofilm-encapsulated nano drug delivery system for the treatment of colon cancer J Microencapsul 2020 37 481 491 10.1080/02652048.2020.1797914 32700606
Shi J, et al. Biofilm-encapsulated nano drug delivery system for the treatment of colon cancer. J Microencapsul. 2020;37:481–91. 10.1080/02652048.2020.1797914.32700606
192. Huang W Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism J Control Release Off J Control Release Soc 2020 317 1 22 10.1016/j.jconrel.2019.11.017
Huang W, et al. Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism. J Control Release Off J Control Release Soc. 2020;317:1–22. 10.1016/j.jconrel.2019.11.017.
193. Meng W Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source Drug Delivery 2020 27 585 598 10.1080/10717544.2020.1748758 32264719
Meng W, et al. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Delivery. 2020;27:585–98. 10.1080/10717544.2020.1748758.32264719
194. Liang Y Duan L Lu J Xia J Engineering exosomes for targeted drug delivery Theranostics 2021 11 3183 3195 10.7150/thno.52570 33537081
Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11:3183–95. 10.7150/thno.52570.33537081
195. Xu X Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration Biomaterials 2021 269 120539 10.1016/j.biomaterials.2020.120539 33243424
Xu X, et al. Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials. 2021;269:120539. 10.1016/j.biomaterials.2020.120539.33243424
196. Liang Y Chondrocyte-targeted microRNA delivery by engineered exosomes toward a cell-free osteoarthritis therapy ACS Appl Mater Interfaces 2020 12 36938 36947 10.1021/acsami.0c10458 32814390
Liang Y, et al. Chondrocyte-targeted microRNA delivery by engineered exosomes toward a cell-free osteoarthritis therapy. ACS Appl Mater Interfaces. 2020;12:36938–47. 10.1021/acsami.0c10458.32814390
197. Liang Y Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment Theranostics 2022 12 4866 4878 10.7150/thno.69368 35836795
Liang Y, et al. Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment. Theranostics. 2022;12:4866–78. 10.7150/thno.69368.35836795
198. Liang Y Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading Biomater Sci 2022 10 4095 4106 10.1039/d2bm00480a 35766814
Liang Y, et al. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading. Biomater Sci. 2022;10:4095–106. 10.1039/d2bm00480a.35766814
199. Liang Y Cell-derived nanovesicle-mediated drug delivery to the brain: principles and strategies for vesicle engineering Mol Ther 2022 10.1016/j.ymthe.2022.10.008 36514292
Liang Y, et al. Cell-derived nanovesicle-mediated drug delivery to the brain: principles and strategies for vesicle engineering. Mol Ther. 2022. 10.1016/j.ymthe.2022.10.008.36514292
200. Li DF Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease J Mater Chem B 2022 10 5853 5872 10.1039/d2tb01190e 35876136
Li DF, et al. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease. J Mater Chem B. 2022;10:5853–72. 10.1039/d2tb01190e.35876136
201. Duan L Exosome-mediated delivery of gene vectors for gene therapy Nanoscale 2021 13 1387 1397 10.1039/d0nr07622h 33350419
Duan L, et al. Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale. 2021;13:1387–97. 10.1039/d0nr07622h.33350419
202. Kim JH Lee J Park J Gho YS Gram-negative and Gram-positive bacterial extracellular vesicles Semin Cell Dev Biol 2015 40 97 104 10.1016/j.semcdb.2015.02.006 25704309
Kim JH, Lee J, Park J, Gho YS. Gram-negative and Gram-positive bacterial extracellular vesicles. Semin Cell Dev Biol. 2015;40:97–104. 10.1016/j.semcdb.2015.02.006.25704309
203. Lee JH Transcription factor σB plays an important role in the production of extracellular membrane-derived vesicles in Listeria monocytogenes PLoS ONE 2013 8 e73196 10.1371/journal.pone.0073196 23977379
Lee JH, et al. Transcription factor σB plays an important role in the production of extracellular membrane-derived vesicles in Listeria monocytogenes. PLoS ONE. 2013;8:e73196. 10.1371/journal.pone.0073196.23977379
204. Cuesta CM Guerri C Ureña J Pascual M Role of microbiota-derived extracellular vesicles in gut-brain communication Int J Mol Sci 2021 10.3390/ijms22084235 34884634
Cuesta CM, Guerri C, Ureña J, Pascual M. Role of microbiota-derived extracellular vesicles in gut-brain communication. Int J Mol Sci. 2021. 10.3390/ijms22084235.34884634
205. Schulz E Karagianni A Koch M Fuhrmann G Hot EVs—How temperature affects extracellular vesicles Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 2020 146 55 63 10.1016/j.ejpb.2019.11.010
Schulz E, Karagianni A, Koch M, Fuhrmann G. Hot EVs—How temperature affects extracellular vesicles. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2020;146:55–63. 10.1016/j.ejpb.2019.11.010.
206. Valguarnera E Scott NE Azimzadeh P Feldman MF Surface exposure and packing of lipoproteins into outer membrane vesicles are coupled processes in Bacteroides mSphere 2018 10.1128/mSphere.00559-18 30404931
Valguarnera E, Scott NE, Azimzadeh P, Feldman MF. Surface exposure and packing of lipoproteins into outer membrane vesicles are coupled processes in Bacteroides. mSphere. 2018. 10.1128/mSphere.00559-18.30404931
207. Bryant WA In silico analysis of the small molecule content of outer membrane vesicles produced by Bacteroides thetaiotaomicron indicates an extensive metabolic link between microbe and host Front Microbiol 2017 8 2440 10.3389/fmicb.2017.02440 29276507
Bryant WA, et al. In silico analysis of the small molecule content of outer membrane vesicles produced by Bacteroides thetaiotaomicron indicates an extensive metabolic link between microbe and host. Front Microbiol. 2017;8:2440. 10.3389/fmicb.2017.02440.29276507
208. Zakharzhevskaya NB Interaction of Bacteroides fragilis toxin with outer membrane vesicles reveals new mechanism of its secretion and delivery Front Cell Infect Microbiol 2017 7 2 10.3389/fcimb.2017.00002 28144586
Zakharzhevskaya NB, et al. Interaction of Bacteroides fragilis toxin with outer membrane vesicles reveals new mechanism of its secretion and delivery. Front Cell Infect Microbiol. 2017;7:2. 10.3389/fcimb.2017.00002.28144586
209. Stentz R A bacterial homolog of a eukaryotic inositol phosphate signaling enzyme mediates cross-kingdom dialog in the mammalian gut Cell Rep 2014 6 646 656 10.1016/j.celrep.2014.01.021 24529702
Stentz R, et al. A bacterial homolog of a eukaryotic inositol phosphate signaling enzyme mediates cross-kingdom dialog in the mammalian gut. Cell Rep. 2014;6:646–56. 10.1016/j.celrep.2014.01.021.24529702
210. Hickey CA Colitogenic Bacteroides thetaiotaomicron antigens access host immune cells in a sulfatase-dependent manner via outer membrane vesicles Cell Host Microbe 2015 17 672 680 10.1016/j.chom.2015.04.002 25974305
Hickey CA, et al. Colitogenic Bacteroides thetaiotaomicron antigens access host immune cells in a sulfatase-dependent manner via outer membrane vesicles. Cell Host Microbe. 2015;17:672–80. 10.1016/j.chom.2015.04.002.25974305
211. Alvarez CS Extracellular vesicles and soluble factors secreted by Escherichia coli Nissle 1917 and ECOR63 protect against enteropathogenic E. coli-induced intestinal epithelial barrier dysfunction BMC Microbiol 2019 19 166 10.1186/s12866-019-1534-3 31315566
Alvarez CS, et al. Extracellular vesicles and soluble factors secreted by Escherichia coli Nissle 1917 and ECOR63 protect against enteropathogenic E. coli-induced intestinal epithelial barrier dysfunction. BMC Microbiol. 2019;19:166. 10.1186/s12866-019-1534-3.31315566
212. Chelakkot C Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions Exp Mol Med 2018 50 e450 10.1038/emm.2017.282 29472701
Chelakkot C, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med. 2018;50:e450. 10.1038/emm.2017.282.29472701
213. Ashrafian F Akkermansia muciniphila-derived extracellular vesicles as a mucosal delivery vector for amelioration of obesity in mice Front Microbiol 2019 10 2155 10.3389/fmicb.2019.02155 31632356
Ashrafian F, et al. Akkermansia muciniphila-derived extracellular vesicles as a mucosal delivery vector for amelioration of obesity in mice. Front Microbiol. 2019;10:2155. 10.3389/fmicb.2019.02155.31632356
214. Ashrafian F Comparative study of effect of Akkermansia muciniphila and its extracellular vesicles on toll-like receptors and tight junction Gastroenterol Hepatol Bed Bench 2019 12 163 168 31191842
Ashrafian F, et al. Comparative study of effect of Akkermansia muciniphila and its extracellular vesicles on toll-like receptors and tight junction. Gastroenterol Hepatol Bed Bench. 2019;12:163–8.31191842
215. Fábrega MJ Activation of immune and defense responses in the intestinal mucosa by outer membrane vesicles of commensal and probiotic Escherichia coli strains Front Microbiol 2016 7 705 10.3389/fmicb.2016.00705 27242727
Fábrega MJ, et al. Activation of immune and defense responses in the intestinal mucosa by outer membrane vesicles of commensal and probiotic Escherichia coli strains. Front Microbiol. 2016;7:705. 10.3389/fmicb.2016.00705.27242727
216. Canas MA Fabrega MJ Gimenez R Badia J Baldoma L Outer membrane vesicles from probiotic and commensal Escherichia coli activate NOD1-mediated immune responses in intestinal epithelial cells Front Microbiol 2018 9 498 10.3389/fmicb.2018.00498 29616010
Canas MA, Fabrega MJ, Gimenez R, Badia J, Baldoma L. Outer membrane vesicles from probiotic and commensal Escherichia coli activate NOD1-mediated immune responses in intestinal epithelial cells. Front Microbiol. 2018;9:498. 10.3389/fmicb.2018.00498.29616010
217. Seo MK Park EJ Ko SY Choi EW Kim S Therapeutic effects of kefir grain Lactobacillus-derived extracellular vesicles in mice with 2,4,6-trinitrobenzene sulfonic acid-induced inflammatory bowel disease J Dairy Sci 2018 101 8662 8671 10.3168/jds.2018-15014 30100498
Seo MK, Park EJ, Ko SY, Choi EW, Kim S. Therapeutic effects of kefir grain Lactobacillus-derived extracellular vesicles in mice with 2,4,6-trinitrobenzene sulfonic acid-induced inflammatory bowel disease. J Dairy Sci. 2018;101:8662–71. 10.3168/jds.2018-15014.30100498
218. Maerz JK Outer membrane vesicles blebbing contributes to B. vulgatus mpk-mediated immune response silencing Gut Microbes 2018 9 1 12 10.1080/19490976.2017.1344810 28686482
Maerz JK, et al. Outer membrane vesicles blebbing contributes to B. vulgatus mpk-mediated immune response silencing. Gut Microbes. 2018;9:1–12. 10.1080/19490976.2017.1344810.28686482
219. Al-Nedawi K Gut commensal microvesicles reproduce parent bacterial signals to host immune and enteric nervous systems FASEB J Off Publ Fed Am Soc Exp Biol 2015 29 684 695 10.1096/fj.14-259721
Al-Nedawi K, et al. Gut commensal microvesicles reproduce parent bacterial signals to host immune and enteric nervous systems. FASEB J Off Publ Fed Am Soc Exp Biol. 2015;29:684–95. 10.1096/fj.14-259721.
220. Yamasaki-Yashiki S Miyoshi Y Nakayama T Kunisawa J Katakura Y IgA-enhancing effects of membrane vesicles derived from Lactobacillus sakei subsp. sakei NBRC15893 Biosci Microbiota Food Health 2019 38 23 29 10.12938/bmfh.18-015 30705799
Yamasaki-Yashiki S, Miyoshi Y, Nakayama T, Kunisawa J, Katakura Y. IgA-enhancing effects of membrane vesicles derived from Lactobacillus sakei subsp. sakei NBRC15893. Biosci Microbiota Food Health. 2019;38:23–9. 10.12938/bmfh.18-015.30705799
221. López P Treg-inducing membrane vesicles from Bifidobacterium bifidum LMG13195 as potential adjuvants in immunotherapy Vaccine 2012 30 825 829 10.1016/j.vaccine.2011.11.115 22172507
López P, et al. Treg-inducing membrane vesicles from Bifidobacterium bifidum LMG13195 as potential adjuvants in immunotherapy. Vaccine. 2012;30:825–9. 10.1016/j.vaccine.2011.11.115.22172507
222. Kim JH Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression J Allergy Clin Immunol 2016 137 507 516.e508 10.1016/j.jaci.2015.08.016 26433560
Kim JH, et al. Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression. J Allergy Clin Immunol. 2016;137:507-516.e508. 10.1016/j.jaci.2015.08.016.26433560
223. Sacks D Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke Int J Stroke Off J Int Stroke Soc 2018 13 612 632 10.1177/1747493018778713
Sacks D, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke Off J Int Stroke Soc. 2018;13:612–32. 10.1177/1747493018778713.
224. Díaz-Garrido N Transcriptomic microRNA Profiling of dendritic cells in response to gut microbiota-secreted vesicles Cells 2020 10.3390/cells9061534 32585977
Díaz-Garrido N, et al. Transcriptomic microRNA Profiling of dendritic cells in response to gut microbiota-secreted vesicles. Cells. 2020. 10.3390/cells9061534.32585977
